Antigen binding polypeptides, polypeptide complexes and methods of use thereof

Abstract

Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells, pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.

Description

ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOFCROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims priority benefit to U.S. Provisional Appl. No. 63 / 574, 175, filed April 3,2024, the contents of which are hereby incorporated by reference in its entirety.REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

[0002] The content of the electronically submitted Sequence Listing XML (Name:4850_0150001_SequenceListing_ST26.xml; Size: 2,631,424 bytes; and Date of Creation: April 2, 2025), filed with the application, is incorporated herein by reference in its entirety.FIELD OF THE INVENTION

[0003] The present disclosure relates to anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antigen binding polypeptides and polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural features. The present disclosure further relates to antigen binding polypeptides and polypeptide complexes (e.g., antibodies and antigen binding fragments thereof), having certain structural features, which have the ability to bind to one or more antigens, such as infectious disease antigens (including viral antigens (including viral antigens that are not sarbecovirus antigens), bacterial antigens, and parasite antigens); tumor-associated antigens; or antigens associated with pathologies other than infectious diseases and cancer / tumor. The present disclosure also relates to polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells; pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0004] This invention was made in the performance of a Cooperative Research and DevelopmentAgreement with the National Institutes of Health, an Agency of the Department of Health and Human Services. The Government has certain rights in this invention.BACKGROUND

[0005] The outbreak of severe acute respiratory syndrome coronavirus (SARS-CoV-2) has caused over450 million infections and over 6.9 million deaths worldwide. SARS-CoV-2 is the strain of coronavirus that causes CO VID-19 (coronavirus disease 2019). Sequencing and publication of the original Wuhan Hu- 1 (WA-1) genome enabled rapid vaccine design and production of spike proteins for therapeutic antibody development. However, persistent circulation of viruses during human pandemics leads to genetic variationthat resists containment and eradication. While cellular and humoral immune responses are needed for optimal protection against viral infection, neutralizing antibodies play a major role in prevention and eradication of pathogens.

[0006] SARS-CoV-2 spike protein mutants and SARS-CoV-2 variants D614G spike protein mutant (e.g.,D614G), Alpha variant (e.g., B.1.1.7), Beta variant (e.g., B.1.351), Gamma variant (e.g., P. l), Delta variant (e.g., B.1.617.2 or AY.l), Kappa variant (e.g., B.1.617.1), Iota variant (e.g., B.1.526), Lambda variant (e.g., C.37), Epsilon variant (e.g., B.1.427), Mu variant (e.g., B.1.621), Theta variant, Zeta variant, R.l variant, C.1.2 variant, and Omicron variant (e.g., B.1.1.529, BA. l, BA.2, BA.2.12.1, BAA, BA.4 / 5, BA.5, BQ.l, BQ.1.1, BA.2.75, BA.2.75.2, BA.4.6, BQ.1.1, BJ.l, XBB, XBB1.5, BF.7, CH.1.1, BA.2.86, EG.5, JN.l, JD.1, EG.5.1, FL.1.5.1, HK.3, HV. l, JD.1.1, JF.l, XBB.1, XBB.1.16, XBB.1.16.6, XBB.2.3.2, JN.l.13.1, KP.2, JN.l.16, JN.l.16.1, JN.l.13, JN. l.18, KP.2.3, LB.l, KP.3, or KP.3.1.1) have emerged to contain mutations that are resistant to current therapies, have increased pathogenicity, and evade current vaccines. This led to their classification as variants of concern (VOCs).

[0007] Therapeutic antibodies have emerged as an important class of agents for treating human diseases and disorders. Therapeutic antibodies have been engineered to have specificity for one or two or more different antigens or epitopes. "Monospecific" antibodies, including engineered monospecific antibodies, are antibodies that have specificity for one antigen or epitope. "Multispecific" antibodies are, for example, bispecific, trispecific, or tetraspecific antibodies, which are antibodies that have been engineered to have specificity for two, three, or four different antigens or epitopes, respectively. Monospecific and multispecific antibodies have been used to form multi-targeting strategies to treat human diseases and disorders, and are an important technological platform for developing neutralizing antibody -based therapeutics for preventing and treating SARS-CoV-2 infection and COVID-19.

[0008] There is a need for improved therapies to prevent and treat SARS-CoV-2 infection and CO VID-19. There is a need for therapeutic antibodies with broad VOC reactivity and resistance to SARS-CoV-2 escape. There is also a need for therapeutic antibodies that are easier to manufacture and administer than current therapeutic antibody cocktails. There is also a need to treat or prevent SARS-CoV-2 infection and COVID-19 in immunocompromised individuals who cannot mount an effective immune response through vaccinations.

[0009] Therapeutic antibodies have emerged as an important class of agents for treating human diseases and disorders. Therapeutic antibodies have been engineered to have specificity for one or two or more different antigens or epitopes. "Monospecific" antibodies, including engineered monospecific antibodies, are antibodies that have specificity for one antigen or epitope. "Multispecific" antibodies are, for example, bispecific, trispecific, or tetraspecific antibodies, which are antibodies that have been engineered to have specificity for two, three, or four different antigens or epitopes, respectively. Monospecific and multispecific antibodies have been used to form multi-targeting strategies to treat human pathologies, and are an important technological platform for developing antibody -based therapeutics for preventing and treating pathologies, such as infectious diseases (such as viral infections (including non-sarbecovirus infections), bacterial infections, and parasite infections); cancers / tumors; and pathologies other than infectious diseases and cancers / tumors.

[0010] There is a need for improved therapies to prevent and treat pathologies. There is also a need for therapeutic antibodies that are easier to manufacture and administer than current therapeutic antibody cocktails. There is also a need to treat or prevent pathologies in immunocompromised individuals who cannot mount an effective immune response through vaccinations.BRIEF SUMMARY

[0011] Provided herein is an antigen binding polypeptide having a structure, from amino-terminus to carboxy-terminus, represented by: VL1-L1-CL-L2-VL2-L3-VH2-L4-VH1-L5-CH1; VL1-L1-CL-L2-VH2- L3-VL2-L4-VH1-L5-CH1; VL1-L1-CH1-L2-VL2-L3-VH2-L4-VH1-L5-CL; VL1-L1-CH1-L2-VH2-L3- VL2-L4-VH1-L5-CL; VH1-L1-CL-L2-VL2-L3-VH2-L4-VL1-L5-CH1; VH1-L1-CL-L2-VH2-L3-VL2- L4-VL 1 -L5-CH 1 ; VH 1 -L 1 -CH 1 -L2-VL2-L3 -VH2-L4-VL 1 -L5-CL; VH 1 -L 1-CH 1 -L2-VH2-L3 -VL2-L4- VL1-L5-CL; VL2-L1-CL-L2-VL1-L3-VH1-L4-VH2-L5-CH1; VL2-L1-CL-L2-VH1-L3-VL1-L4-VH2-L5- CHI; VL2-L1-CH1-L2-VL1-L3-VH1-L4-VH2-L5-CL; VL2-L1-CH1-L2-VH1-L3-VL1-L4-VH2-L5-CL; VH2-L 1 -CL-L2-VL 1 -L3 -VH 1 -L4-VL2-L5-CH 1 ; VH2-L 1 -CL-L2-VH 1 -L3 -VL 1 -L4-VL2-L5-CH 1 ; VH2- L1-CH1-L2-VL1-L3-VH1-L4-VL2-L5-CL; or VH2-L1-CH1-L2-VH1-L3-VL1-L4-VL2-L5-CL; wherein: VL1 is a first immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein; VL2 is a second immunoglobulin light chain variable region that specifically binds to a SARS-CoV-2 protein; VH1 is a first immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; VH2 is a second immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; CL is an immunoglobulin light chain constant region; CHI is an immunoglobulin heavy chain constant region 1; and L1-L5 are optional amino acid linkers.

[0012] Also provided herein is an antigen binding polypeptide having a structure, from amino -terminus to carboxy-terminus, represented by: VL1-CL-L1-VL2-L2-VH2-L3-VH1-CH1; VL1-CL-L1-VH2-L2-VL2- L3-VH1-CH1; VL1-CH1-L1-VL2-L2-VH2-L3-VH1-CL; VL1-CH1-L1-VH2-L2-VL2-L3-VH1-CL; VH1- CL-L 1 -VL2-L2-VH2-L3 -VL 1 -CH 1 ; VH 1-CL-L 1-VH2-L2-VL2-L3 -VL 1 -CH 1 ; VH 1 -CH 1 -L 1 -VL2-L2- VH2-L3-VL1-CL; VH1-CH1-L1-VH2-L2-VL2-L3-VL1-CL; VL2-CL-L1-VL1-L2-VH1-L3-VH2-CH1; VL2-CL-L1-VH1-L2-VL1-L3-VH2-CH1; VL2-CH1-L1-VL1-L2-VH1-L3-VH2-CL; VL2-CH1-L1-VH1- L2-VL 1 -L3 -VH2-CL; VH2-CL-L 1 -VL 1 -L2-VH 1 -L3 -VL2-CH 1 ; VH2-CL-L 1 -VH 1 -L2-VL 1 -L3-VL2- CH1; VH2-CH1-L1-VL1-L2-VH1-L3-VL2-CL; or VH2-CH1-L1-VH1-L2-VL1-L3-VL2-CL; wherein: VL1 is a first immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein; VL2 is a second immunoglobulin light chain variable region that specifically binds to a SARS-CoV-2 protein; VH1 is a first immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; VH2 is a second immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; CL is an immunoglobulin light chain constant region; CHI is an immunoglobulin heavy chain constant region 1; and L1-L3 are amino acid linkers

[0013] Also provided herein is an antigen binding polypeptide having a structure, from amino-terminus to carboxy-terminus, represented by: VL1-L1-VH1-L2-VL2-L3-CL-L4-VH2-L5-CH1; VL1-L1-VH1-L2-VL2-L3 -CH 1 -L4-VH2-L5-CL; VL 1 -L 1 -VH 1 -L2-VH2-L3 -CL-L4-VL2-L5-CH 1 ; VL 1-L 1 -VH 1 -L2-VH2- L3-CH1-L4-VL2-L5-CL; VL1-L1-VL2-L2-VH1-L3-CL-L4-VH2-L5-CH1; VL1-L1-VL2-L2-VH1-L3- CH 1 -L4-VH2-L5-CL; VL 1 -L 1 -VH2-L2-VH 1 -L3 -CL-L4-VL2-L5-CH 1 ; VL 1 -L 1-VH2-L2-VH 1-L3 -CH 1 - L4-VL2-L5-CL; VH1-L1-VL1-L2-VL2-L3-CL-L4-VH2-L5-CH1; VH1-L1-VL1-L2-VL2-L3-CH1-L4- VH2-L5-CL; VH 1 -L 1 -VL 1 -L2-VH2-L3 -CL-L4-VL2-L5-CH 1 ; VH 1-L 1 -VL 1 -L2-VH2-L3 -CH 1 -L4-VL2- L5-CL; VH1-L1-VL2-L2-VL1-L3-CL-L4-VH2-L5-CH1; VH1-L1-VL2-L2-VL1-L3-CH1-L4-VH2-L5-CL; VH 1 -L 1-VH2-L2-VL 1 -L3 -CL-L4-VL2-L5-CH 1 ; VH 1 -L 1 -VH2-L2-VL 1-L3 -CH 1 -L4-VL2-L5-CL; VL2- L1-VL1-L2-VH2-L3-CL-L4-VH1-L5-CH1; VL2-L1-VL1-L2-VH2-L3-CH1-L4-VH1-L5-CL; VL2-L1- VH1-L2-VH2-L3-CL-L4-VL1-L5-CH1; VL2-L1-VH1-L2-VH2-L3-CH1-L4-VL1-L5-CL; VL2-L1-VH2- L2-VL1-L3-CL-L4-VH1-L5-CH1; VL2-L1-VH2-L2-VL1-L3-CH1-L4-VH1-L5-CL; VL2-L1-VH2-L2- VH 1 -L3 -CL-L4-VL 1 -L5-CH 1 ; VL2-L 1 -VH2-L2-VH 1 -L3 -CH 1 -L4-VL 1 -L5-CL; VH2-L 1 -VL 1 -L2-VL2- L3-CL-L4-VH1-L5-CH1; VH2-L1-VL1-L2-VL2-L3-CH1-L4-VH1-L5-CL; VH2-L1-VH1-L2-VL2-L3- CL-L4-VL1-L5-CH1; VH2-L1-VH1-L2-VL2-L3-CH1-L4-VL1-L5-CL; VH2-L1-VL2-L2-VL1-L3-CL-L4- VH 1 -L5-CH 1 ; VH2-L 1 -VL2-L2-VL 1 -L3 -CH 1 -L4-VH 1 -L5-CL; VH2-L 1-VL2-L2-VH 1 -L3 -CL-L4-VL 1 - L5-CH1; or VH2-L1-VL2-L2-VH1-L3-CH1-L4-VL1-L5-CL; wherein: VL1 is a first immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein; VL2 is a second immunoglobulin light chain variable region that specifically binds to a SARS-CoV-2 protein; VH1 is a first immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; VH2 is a second immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; CL is an immunoglobulin light chain constant region; CHI is an immunoglobulin heavy chain constant region 1; and L1-L5 are optional amino acid linkers.

[0014] Also provided herein is an antigen binding polypeptide having a structure, from amino -terminus to carboxy-terminus, represented by: VL1-L1-CL-L2-VH1-L3-CH1-L4-VL2-L5-VH2; VL1-L1-CL-L2-VH1- L3-CH1-L4-VH2-L5-VL2; VL1-L1-CL-L2-VL2-L3-CH1-L4-VH1-L5-VH2; VL1-L1-CL-L2-VH2-L3- CH1-L4-VH1-L5-VL2; VL1-L1-CH1-L2-VH1-L3-CL-L4-VL2-L5-VH2; VL1-L1-CH1-L2-VH1-L3-CL- L4-VH2-L5-VL2; VL1-L1-CH1-L2-VL2-L3-CL-L4-VH1-L5-VH2; VL1-L1-CH1-L2-VH2-L3-CL-L4- VH1-L5-VL2; VH1-L1-CL-L2-VL1-L3-CH1-L4-VL2-L5-VH2; VH1-L1-CL-L2-VL1-L3-CH1-L4-VH2- L5-VL2; VH1-L1-CL-L2-VL2-L3-CH1-L4-VL1-L5-VH2; VH1-L1-CL-L2-VH2-L3-CH1-L4-VL1-L5- VL2; VH1-L1-CH1-L2-VL1-L3-CL-L4-VL2-L5-VH2; VH1-L1-CH1-L2-VL1-L3-CL-L4-VH2-L5-VL2; VH1-L1-CH1-L2-VL2-L3-CL-L4-VL1-L5-VH2; VH1-L1-CH1-L2-VH2-L3-CL-L4-VL1-L5-VL2; VL2- L1-CL-L2-VL1-L3-CH1-L4-VH2-L5-VH1; VL2-L1-CL-L2-VH1-L3-CH1-L4-VH2-L5-VL1; VL2-L1-CL- L2-VH2-L3 -CH 1 -L4-VL 1 -L5-VH 1 ; VL2-L 1 -CL-L2-VH2-L3-CH 1 -L4-VH 1 -L5-VL 1 ; VL2-L 1 -CH 1 -L2- VL 1 -L3 -CL-L4-VH2-L5-VH 1 ; VL2-L 1 -CH 1 -L2-VH 1 -L3 -CL-L4-VH2-L5-VL 1 ; VL2-L 1 -CH 1-L2-VH2- L3-CL-L4-VL1-L5-VH1; VL2-L1-CH1-L2-VH2-L3-CL-L4-VH1-L5-VL1; VH2-L1-CL-L2-VL1-L3-CH1- L4-VL2-L5-VH1; VH2-L1-CL-L2-VH1-L3-CH1-L4-VL2-L5-VL1; VH2-L1-CL-L2-VL2-L3-CH1-L4- VL1-L5-VH1; VH2-L1-CL-L2-VL2-L3-CH1-L4-VH1-L5-VL1; VH2-L1-CH1-L2-VL1-L3-CL-L4-VL2- L5-VH1; VH2-L1-CH1-L2-VH1-L3-CL-L4-VL2-L5-VL1; VH2-L1-CH1-L2-VL2-L3-CL-L4-VL1-L5- VH1; or VH2-L1-CH1-L2-VL2-L3-CL-L4-VH1-L5-VL1; wherein: VL1 is a first immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein; VL2 is a second immunoglobulin light chain variable region that specifically binds to a SARS-CoV-2 protein; VH1 is a first immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; VH2 is a second immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; CL is an immunoglobulin light chain constant region; CHI is an immunoglobulin heavy chain constant region 1; and L1-L5 are optional amino acid linkers.

[0015] In some aspects and in any one of the formulas depicted herein (a) VL1 comprises: (i) a complementarity determining region (CDR) 1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 1, 9, 15, 23, 30, 41, 48, 55, 58, 65, 72, 79, 86, 93, 99, 105, 112, 119, 130, 138, 145, 152, 159, 166, 172, 179, 186, 192, 199, 205, 212, 219, 226, 232, 324, 627, 770, 778, 785, 794, 801, 807, 814, 827, 836, 849, 858, 865, 878, 1045, 1050, 1055, 1060, and 1065; (ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 2, 31, 628, 1046, 1051, 1056, and1061, or at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of amino acid sequences AAS, GAS, LGS, GTN, GTN, SAS, SDS, DNT, EVT, DAS, DVT, RNS, DVS, EDS, DDS, KDS, NNN, SYN, WAS, and DAT; and (iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 3, 10, 16, 24, 32, 38, 42, 49, 59, 66, 73, 80, 87, 94, 100, 106, 113, 120, 126, 131, 139, 146, 153, 160, 167, 173, 180, 187, 193,200, 206, 213, 220, 227, 233, 239, 242, 246, 249, 256, 283, 285, 287, 288, 290, 292, 294, 296, 301, 304,306, 309, 311, 313, 316, 325, 326, 329, 764, 766, 768, 771, 779, 786, 792, 795, 808, 815, 821, 830, 837,843, 850, 856, 859, 866, 872, 879, 885, and 1066; (b) VH1 comprises (i) a CDR1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 5, 12, 18, 26, 34, 44, 51, 61, 68, 75, 82, 89, 96, 102, 108, 115, 122, 133, 141, 148, 155, 162, 175, 182, 189, 195, 202, 208, 215, 222, 229, 235, 318, 629, 773, 781, 788, 797, 803, 810, 817, 823, 832, 839, 845, 852, 861, 868, 874, 881, 1047, 1052, 1057,1062, and 1067; (ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 6, 19, 27, 35, 45, 52, 56, 62, 69, 76, 83, 90, 109, 116, 123, 134, 142, 149, 156, 163, 169, 176, 183, 196, 209, 216, 223, 236, 273, 319, 328, 630, 776, 782, 789, 798, 804, 811, 818, 824, 833, 840, 846, 853, 862, 869, 875, 882, 1048, 1053, 1058, 1063, and 1068; and (iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 7, 13, 20, 28, 36, 40, 46, 53, 63, 70, 77, 84, 91, 97, 103,110, 117, 124, 128, 135, 143, 150, 157, 164, 170, 177, 184, 190, 197, 203, 210, 217, 224, 230, 237, 241,244, 248, 253, 257, 259, 261, 263, 265, 267, 269, 271, 274, 276, 278, 281, 297, 320, 322, 327, 330, 332,631, 765, 767, 769, 774, 783, 790, 793, 799, 805, 812, 819, 825, 834, 841, 847, 854, 857, 863, 870, 876,883, 886, 1049, 1054, 1059, 1064, and 1069; (c) VL2 comprises (i) a complementarity determining region (CDR) 1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 1, 9, 15,23, 30, 41, 48, 55, 58, 65, 72, 79, 86, 93, 99, 105, 112, 119, 130, 138, 145, 152, 159, 166, 172, 179, 186, 192, 199, 205, 212, 219, 226, 232, 324, 627, 770, 778, 785, 794, 801, 807, 814, 827, 836, 849, 858, 865, 878, 1045, 1050, 1055, 1060, and 1065; (ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 2, 31, 628, 1046, 1051, 1056, and 1061, or at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of amino acid sequences AAS, GAS, LGS, GTN, GTN, SAS, SDS, DNT, EVT, DAS, DVT, RNS, DVS, EDS, DDS, KDS, NNN, SYN, WAS, and DAT; and (iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 3, 10, 16, 24, 32, 38, 42, 49, 59, 66, 73, 80, 87, 94, 100,106, 113, 120, 126, 131, 139, 146, 153, 160, 167, 173, 180, 187, 193, 200, 206, 213, 220, 227, 233, 239,242, 246, 249, 256, 283, 285, 287, 288, 290, 292, 294, 296, 301, 304, 306, 309, 311, 313, 316, 325, 326,329, 764, 766, 768, 771, 779, 786, 792, 795, 808, 815, 821, 830, 837, 843, 850, 856, 859, 866, 872, 879,885, and 1066; and (d) VH2 comprises (i) a CDR1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 5, 12, 18, 26, 34, 44, 51, 61, 68, 75, 82, 89, 96, 102, 108, 115, 122, 133, 141, 148, 155, 162, 175, 182, 189, 195, 202, 208, 215, 222, 229, 235, 318, 629, 773, 781, 788, 797, 803, 810, 817, 823, 832, 839, 845, 852, 861, 868, 874, 881, 1047, 1052, 1057, 1062, and 1067; (ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 6, 19, 27, 35, 45, 52, 56, 62, 69, 76, 83, 90, 109, 116, 123, 134, 142, 149, 156, 163, 169, 176, 183, 196, 209, 216, 223, 236, 273, 319, 328, 630, 776, 782, 789, 798, 804, 811, 818, 824, 833, 840, 846, 853, 862, 869, 875, 882, 1048, 1053, 1058, 1063, and 1068; and (iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 7, 13, 20, 28, 36, 40, 46, 53, 63, 70, 77, 84, 91, 97, 103, 110, 117, 124, 128, 135, 143, 150, 157, 164, 170, 177, 184, 190, 197, 203, 210, 217, 224, 230, 237, 241, 244, 248, 253, 257, 259, 261, 263,265, 267, 269, 271, 274, 276, 278, 281, 297, 320, 322, 327, 330, 332, 631, 765, 767, 769, 774, 783, 790,793, 799, 805, 812, 819, 825, 834, 841, 847, 854, 857, 863, 870, 876, 883, 886, 1049, 1054, 1059, 1064, and 1069.

[0016] In some aspects and in any one of the formulas depicted herein (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 4, 11, 17, 25, 33, 39, 43, 50, 60, 67, 74, 81, 88, 95, 101, 107, 114, 121, 127, 132, 140, 147, 154, 161, 168, 174, 181, 188, 194, 201, 207, 214, 221, 228, 234, 240, 243, 247, 250, 251, 252, 255, 284, 286, 289, 291, 293, 295, 299, 300, 302, 303, 305, 307, 308, 310, 312, 314, 315, 317, 323, 772, 780, 787, 796, 802, 809, 816, 822, 831, 838, 844, 851, 860, 867, 873, 880, and 988; (b) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 8, 14, 21, 22, 29, 37, 47, 54, 57, 64, 71, 78, 85, 92, 98, 104, 111, 118, 125, 129, 136, 137, 144, 151, 158, 165, 171, 178, 185, 191, 198, 204, 211, 218, 225, 231, 238, 245, 254, 258, 260, 262, 264,266, 268, 270, 272, 275, 277, 279, 280, 282, 298, 321, 331, 626, 775, 777, 784, 791, 800, 806, 813, 820, 826, 835, 842, 848, 855, 864, 871, 877, and 884; (c) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 4, 11, 17, 25, 33, 39, 43, 50, 60, 67, 74, 81, 88, 95, 101, 107,114, 121, 127, 132, 140, 147, 154, 161, 168, 174, 181, 188, 194, 201, 207, 214, 221, 228, 234, 240, 243,247, 250, 251, 252, 255, 284, 286, 289, 291, 293, 295, 299, 300, 302, 303, 305, 307, 308, 310, 312, 314,315, 317, 323, 772, 780, 787, 796, 802, 809, 816, 822, 831, 838, 844, 851, 860, 867, 873, 880, and 988; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 8, 14, 21,22, 29, 37, 47, 54, 57, 64, 71, 78, 85, 92, 98, 104, 111, 118, 125, 129, 136, 137, 144, 151, 158, 165, 171,178, 185, 191, 198, 204, 211, 218, 225, 231, 238, 245, 254, 258, 260, 262, 264, 266, 268, 270, 272, 275,277, 279, 280, 282, 298, 321, 331, 626, 775, 777, 784, 791, 800, 806, 813, 820, 826, 835, 842, 848, 855,864, 871, 877, and 884.

[0017] In some aspects and in any one of the formulas shown herein, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332.

[0018] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ IDNO: 17; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29.

[0019] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059.

[0020] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14.

[0021] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059.

[0022] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14.

[0023] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325; (b) VL2comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1 or 324, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 2 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 3; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 5, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 7.

[0024] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 4; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 8.

[0025] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 30, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 31 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 32, 38, or 326; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 34, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 35, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 36, 40, or 327.

[0026] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 33 or 39; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 37.

[0027] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631.

[0028] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626.

[0029] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, atleast 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059.

[0030] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14.

[0031] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

[0032] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

[0033] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 152 or 1045, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1046 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 153 or 766; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 155 or 1047, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 156 or 1048, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 157, 767, or 1049.

[0034] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 154; (c) VH1comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 158.

[0035] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631.

[0036] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626.

[0037] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical toSEQ ID NO: 152 or 1045, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1046 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 153 or 766; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 155 or 1047, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 156 or 1048, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 157, 767, or 1049; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631.

[0038] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 154; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 158; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626.

[0039] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acidsequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 152 or 1045, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1046 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to the amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 153 or 766; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 155 or 1047, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 156 or 1048, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 157, 767, or 1049.

[0040] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 154; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 158. In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054.

[0041] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151.

[0042] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628, or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054.

[0043] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151.

[0044] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 152 or 1045, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1046 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 153 or 766; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, atleast 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 155 or 1047, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 156 or 1048, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 157, 767, or 1049.

[0045] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 154; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 158.

[0046] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 172 or 1060, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1061 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence DAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 173 or 792; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 175 or 1062, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, atleast 95%, at least 99%, or 100% identical to SEQ ID NO: 176 or 1063, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 177, 793, or 1064.

[0047] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 174; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 178.

[0048] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 138 or 1065, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1061 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence DAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 139, 856, or 1066; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 152 or 1045, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1046 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 153 or 766; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 141 or 1067, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 142 or 1068, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 143, 857, or 1069; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 155 or 1047, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 156 or 1048, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 157, 767, or 1049.

[0049] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 140; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 154; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 144; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 158.

[0050] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054.

[0051] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147; (c) VH1comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151.

[0052] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 152 or 1045, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1046 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 153 or 766; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 152 or 1045, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1046 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 153 or 766; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 155 or 1047, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 156 or 1048, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 157, 767, or 1049; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 155 or 1047, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 156 or 1048, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 157, 767, or 1049.

[0053] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 154; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 154; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 158; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 158.

[0054] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059.

[0055] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14.

[0056] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN,and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

[0057] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

[0058] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least7Q° / o, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

[0059] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

[0060] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332.

[0061] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical SEQ ID NO: 14; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29.

[0062] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1 or 324, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 2 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 3; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 5, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 7; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332.

[0063] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 4; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 8; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29.

[0064] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 30, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 31 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 32, 38, or 326; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 34, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 35, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 36, 40, or 327; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

[0065] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 33 or 39; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; (c)VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 37; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

[0066] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

[0067] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

[0068] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical toSEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332.

[0069] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29.

[0070] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1 or 324, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 2 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 3; (b) VL2 comprises a CDR1 having an amino acid sequenceat least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 5, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 7; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332.

[0071] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 4; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 8; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29.

[0072] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, atleast 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

[0073] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

[0074] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 30, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 31 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 32, 38, or 326; (b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; (c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 34, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 35, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 36, 40 or 327; and (d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, atleast 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

[0075] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 33 or 39; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; (c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 37; and (d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

[0076] Also provided herein is an antigen binding polypeptide having a structure, from amino-terminus to carboxy-terminus, represented by: VL1-L1-CL-L2-VH1-L3-CH1; VL1-L1-CH1-L2-VH1-L3-CL; VH1-L1- CL-L2-VL1-L3-CH1; or VH1-L1-CH1-L2-VL1-L3-CL; wherein: VL1 is an immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein; VH1 is an immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; CL is an immunoglobulin light chain constant region; CHI is an immunoglobulin heavy chain constant region 1; and L1-L3 are optional amino acid linkers.

[0077] In some aspects, (a) VL1 comprises: (i) a complementarity determining region (CDR) 1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 1, 9, 15, 23, 30, 41, 48, 55, 58, 65, 72, 79, 86, 93, 99, 105, 112, 119, 130, 138, 145, 152, 159, 166, 172, 179, 186, 192, 199, 205, 212, 219, 226, 232, 324, 627, 770, 778, 785, 794, 801, 807, 814, 827, 836, 849, 858, 865, 878, 1045, 1050, 1055, 1060, and 1065; (ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 2, 31, 628, 1046, 1051, 1056, and 1061, or at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of amino acid sequences AAS, GAS, LGS, GTN, GTN, SAS, SDS, DNT, EVT, DAS, DVT, RNS, DVS, EDS, DDS, KDS, NNN, SYN, WAS, and DAT; and (iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 3, 10, 16, 24, 32, 38, 42, 49, 59, 66, 73, 80, 87, 94, 100, 106, 113, 120, 126, 131, 139, 146, 153, 160, 167, 173, 180, 187, 193, 200, 206, 213, 220, 227, 233, 239, 242, 246, 249, 256, 283, 285,287, 288, 290, 292, 294, 296, 301, 304, 306, 309, 311, 313, 316, 325, 326, 329, 764, 766, 768, 771, 779,786, 792, 795, 808, 815, 821, 830, 837, 843, 850, 856, 859, 866, 872, 879, 885, and 1066; and (b) VH1 comprises (i) a CDR1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 5, 12, 18, 26, 34, 44, 51, 61, 68, 75, 82, 89, 96, 102, 108, 115, 122, 133, 141, 148, 155, 162, 175, 182, 189, 195, 202, 208, 215, 222, 229, 235, 318, 629, 773, 781, 788, 797, 803, 810, 817, 823, 832, 839, 845, 852, 861, 868, 874, 881, 1047, 1052, 1057, 1062, and 1067; (ii) a CDR2 having an amino acid sequencethat is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 6, 19, 27, 35, 45, 52, 56, 62, 69, 76, 83, 90, 109, 116, 123, 134, 142, 149, 156, 163, 169, 176, 183, 196, 209, 216, 223, 236, 273, 319, 328, 630, 776, 782, 789, 798, 804, 811, 818, 824, 833, 840, 846, 853, 862, 869, 875, 882, 1048, 1053, 1058, 1063, and 1068; and (iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 7, 13, 20, 28, 36, 40, 46, 53, 63, 70, 77, 84, 91, 97, 103, 110, 117, 124, 128, 135, 143, 150, 157, 164, 170, 177, 184, 190, 197, 203, 210, 217, 224, 230, 237, 241, 244, 248, 253, 257, 259, 261, 263, 265, 267, 269, 271, 274, 276, 278, 281, 297, 320, 322, 327, 330, 332, 631, 765, 767, 769, 774, 783, 790, 793, 799, 805, 812, 819, 825, 834, 841, 847, 854, 857, 863, 870, 876, 883, 886, 1049, 1054, 1059, 1064, and 1069.

[0078] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 4, 11, 17, 25, 33, 39, 43, 50, 60, 67, 74, 81, 88, 95, 101, 107, 114, 121, 127, 132, 140, 147, 154, 161, 168, 174, 181, 188, 194, 201, 207, 214, 221, 228, 234, 240, 243, 247, 250, 251, 252, 255, 284, 286, 289, 291, 293, 295, 299, 300, 302, 303, 305, 307, 308, 310, 312, 314, 315, 317, 323, 772, 780, 787, 796, 802, 809, 816, 822, 831, 838, 844, 851, 860, 867, 873, 880, and 988; and (b) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 8, 14, 21, 22, 29, 37, 47, 54, 57, 64, 71, 78, 85, 92, 98, 104, 111, 118, 125, 129, 136, 137, 144, 151, 158, 165, 171, 178, 185, 191, 198, 204, 211, 218, 225, 231, 238, 245, 254, 258, 260, 262, 264, 266, 268, 270, 272, 275, 277, 279, 280, 282, 298, 321, 331, 626, 775, 777, 784, 791, 800, 806, 813, 820, 826, 835, 842, 848, 855, 864, 871, 877, and 884.

[0079] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; and (b) VH1 comprises a CDR1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059.

[0080] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; and (b) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14.

[0081] Also provided herein is an antigen binding polypeptide having a structure, from amino -terminus to carboxy-terminus, represented by: VL1-L1-VH1-L2-CL; or VH1-L1-VL1-L2-CL; wherein: VL1 is an immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein; VH1 is an immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; CL is an immunoglobulin light chain constant region; and Ll- L2 are optional amino acid tinkers.

[0082] Also provided herein is an antigen binding polypeptide having a structure, from amino -terminus to carboxy -terminus, represented by : VL 1 -L 1 -VH 1 -L2-CH 1 ; or VH 1 -L 1 -VL 1 -L2-CH 1 ; wherein: VL 1 is an immunoglobulin tight chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein; VH1 is an immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; CHI is an immunoglobulin heavy chain constant region 1; and L1-L2 are optional amino acid tinkers.

[0083] In some aspects, (a) VL1 comprises: (i) a complementarity determining region (CDR) 1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 1, 9, 15, 23, 30, 41, 48, 55, 58, 65, 72, 79, 86, 93, 99, 105, 112, 119, 130, 138, 145, 152, 159, 166, 172, 179, 186, 192, 199, 205, 212, 219, 226, 232, 324, 627, 770, 778, 785, 794, 801, 807, 814, 827, 836, 849, 858, 865, 878, 1045, 1050, 1055, 1060, and 1065; (ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 2, 31, 628, 1046, 1051, 1056, and 1061, or at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of amino acid sequences AAS, GAS, LGS, GTN, GTN, SAS, SDS, DNT, EVT, DAS, DVT, RNS, DVS, EDS, DDS, KDS, NNN, SYN, WAS, and DAT; and (iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 3, 10, 16, 24, 32, 38, 42, 49, 59, 66, 73, 80, 87, 94, 100, 106, 113, 120, 126, 131, 139, 146, 153, 160, 167, 173, 180, 187, 193, 200, 206, 213, 220, 227, 233, 239, 242, 246, 249, 256, 283, 285,287, 288, 290, 292, 294, 296, 301, 304, 306, 309, 311, 313, 316, 325, 326, 329, 764, 766, 768, 771, 779,786, 792, 795, 808, 815, 821, 830, 837, 843, 850, 856, 859, 866, 872, 879, 885, and 1066; and (b) VH1 comprises: (i) a CDR1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 5, 12, 18, 26, 34, 44, 51, 61, 68, 75, 82, 89, 96, 102, 108, 115, 122, 133, 141, 148, 155, 162, 175, 182, 189, 195, 202, 208, 215, 222, 229, 235, 318, 629, 773, 781, 788, 797, 803, 810, 817, 823, 832, 839, 845,852, 861, 868, 874, 881, 1047, 1052, 1057, 1062, and 1067; (ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 6, 19, 27, 35, 45, 52, 56, 62, 69, 76, 83, 90, 109, 116, 123, 134, 142, 149, 156, 163, 169, 176, 183, 196, 209, 216, 223, 236, 273, 319, 328, 630, 776, 782, 789,798, 804, 811, 818, 824, 833, 840, 846, 853, 862, 869, 875, 882, 1048, 1053, 1058, 1063, and 1068; and(iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 7, 13, 20,28, 36, 40, 46, 53, 63, 70, 77, 84, 91, 97, 103, 110, 117, 124, 128, 135, 143, 150, 157, 164, 170, 177, 184,190, 197, 203, 210, 217, 224, 230, 237, 241, 244, 248, 253, 257, 259, 261, 263, 265, 267, 269, 271, 274,276, 278, 281, 297, 320, 322, 327, 330, 332, 631, 765, 767, 769, 774, 783, 790, 793, 799, 805, 812, 819,825, 834, 841, 847, 854, 857, 863, 870, 876, 883, 886, 1049, 1054, 1059, 1064, and 1069.

[0084] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 4, 11, 17, 25, 33, 39, 43, 50, 60, 67, 74, 81, 88, 95, 101, 107, 114, 121, 127, 132, 140, 147,154, 161, 168, 174, 181, 188, 194, 201, 207, 214, 221, 228, 234, 240, 243, 247, 250, 251, 252, 255, 284,286, 289, 291, 293, 295, 299, 300, 302, 303, 305, 307, 308, 310, 312, 314, 315, 317, 323, 772, 780, 787,796, 802, 809, 816, 822, 831, 838, 844, 851, 860, 867, 873, 880, and 988; and (b) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 8, 14, 21, 22, 29, 37, 47, 54, 57, 64, 71, 78, 85, 92, 98, 104, 111, 118, 125, 129, 136, 137, 144, 151, 158, 165, 171, 178, 185, 191, 198, 204, 211, 218, 225, 231, 238, 245, 254, 258, 260, 262, 264, 266, 268, 270, 272, 275, 277, 279, 280, 282, 298, 321, 331, 626, 775, 777, 784, 791, 800, 806, 813, 820, 826, 835, 842, 848, 855, 864, 871, 877, and 884.

[0085] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; and (b) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

[0086] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; and (b) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

[0087] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, atleast 99%, or 100% identical to SEQ ID NO: 10; and (b) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059.

[0088] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; and (b) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14.

[0089] In some aspects, (a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 72, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence DNT, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 73; and (b) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 75, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 76, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 77.

[0090] In some aspects, (a) LI comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 74; and (b) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 78.

[0091] Also provided herein is an antigen binding polypeptide having a structure, from amino-terminus to carboxy-terminus, represented by: VL1-L1-VL2-L2-CH1; or VL2-L1-VL1-L2-CH1; wherein VL1 is a first immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein; VL2 is a second immunoglobulin light chain variable region that specifically binds to a SARS-CoV-2 protein; CHI is an immunoglobulin heavy chain constant region 1; and L1-L2 are optional amino acid linkers.

[0092] In some aspects, (a) VL1 comprises: (i) a complementarity determining region (CDR) 1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 1, 9, 15, 23, 30, 41, 48, 55, 58, 65, 72, 79, 86, 93, 99, 105, 112, 119, 130, 138, 145, 152, 159, 166, 172, 179, 186, 192, 199, 205, 212, 219, 226, 232, 324, 627, 770, 778, 785, 794, 801, 807, 814, 827, 836, 849, 858, 865, 878, 1045, 1050, 1055, 1060, and 1065; (ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 2, 31, 628, 1046, 1051, 1056, and 1061, or at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of amino acid sequences AAS, GAS, LGS, GTN, GTN, SAS, SDS, DNT, EVT, DAS, DVT, RNS, DVS, EDS, DDS, KDS, NNN, SYN, WAS, and DAT; and (iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 3, 10, 16, 24, 32, 38, 42, 49, 59, 66, 73, 80, 87, 94, 100, 106, 113, 120, 126, 131, 139,146, 153, 160, 167, 173, 180, 187, 193, 200, 206, 213, 220, 227, 233, 239, 242, 246, 249, 256, 283, 285,287, 288, 290, 292, 294, 296, 301, 304, 306, 309, 311, 313, 316, 325, 326, 329, 764, 766, 768, 771, 779,786, 792, 795, 808, 815, 821, 830, 837, 843, 850, 856, 859, 866, 872, 879, 885, and 1066; and (b) VL2 comprises: (i) a complementarity determining region (CDR) 1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 1, 9, 15, 23, 30, 41, 48, 55, 58, 65, 72, 79, 86, 93, 99, 105, 112, 119, 130, 138, 145, 152, 159, 166, 172, 179, 186, 192, 199, 205, 212, 219, 226, 232, 324, 627, 770, 778, 785, 794, 801, 807, 814, 827, 836, 849, 858, 865, 878, 1045, 1050, 1055, 1060, and 1065; (ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 2, 31, 628, 1046, 1051, 1056, and 1061, or at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of amino acid sequences AAS, GAS, LGS, GTN, GTN, SAS, SDS, DNT, EVT, DAS, DVT, RNS, DVS, EDS, DDS, KDS, NNN, SYN, WAS, and DAT; and (iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 3, 10, 16, 24, 32, 38, 42, 49, 59, 66, 73, 80, 87, 94, 100, 106, 113, 120, 126, 131, 139, 146, 153, 160, 167, 173, 180, 187,193, 200, 206, 213, 220, 227, 233, 239, 242, 246, 249, 256, 283, 285, 287, 288, 290, 292, 294, 296, 301,304, 306, 309, 311, 313, 316, 325, 326, 329, 764, 766, 768, 771, 779, 786, 792, 795, 808, 815, 821, 830,837, 843, 850, 856, 859, 866, 872, 879, 885, and 1066.

[0093] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 4, 11, 17, 25, 33, 39, 43, 50, 60, 67, 74, 81, 88, 95, 101, 107, 114, 121, 127, 132, 140, 147,154, 161, 168, 174, 181, 188, 194, 201, 207, 214, 221, 228, 234, 240, 243, 247, 250, 251, 252, 255, 284,286, 289, 291, 293, 295, 299, 300, 302, 303, 305, 307, 308, 310, 312, 314, 315, 317, 323, 772, 780, 787,796, 802, 809, 816, 822, 831, 838, 844, 851, 860, 867, 873, 880, and 988; and (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 4, 11, 17, 25, 33, 39, 43, 50, 60, 67,74, 81, 88, 95, 101, 107, 114, 121, 127, 132, 140, 147, 154, 161, 168, 174, 181, 188, 194, 201, 207, 214,221, 228, 234, 240, 243, 247, 250, 251, 252, 255, 284, 286, 289, 291, 293, 295, 299, 300, 302, 303, 305,307, 308, 310, 312, 314, 315, 317, 323, 772, 780, 787, 796, 802, 809, 816, 822, 831, 838, 844, 851, 860,867, 873, 880, and 988.

[0094] Also provided herein is an antigen binding polypeptide having a structure, from amino -terminus to carboxy -terminus, represented by: VH1-L1-VH2-L2-CL; or VH2-L1-VH1-L2-CL; wherein VH1 is a first immunoglobulin heavy chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein; VH2 is a second immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; CL is an immunoglobulin light chain constant region; and Ll- L2 are optional amino acid linkers.

[0095] In some aspects, (a) VH1 comprises: (i) a CDR1 having an amino acid sequence that is at least65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 5, 12, 18, 26, 34, 44, 51, 61, 68, 75, 82, 89, 96, 102, 108, 115, 122, 133, 141, 148, 155, 162, 175, 182, 189, 195, 202, 208, 215, 222, 229, 235, 318, 629, 773, 781, 788, 797, 803, 810, 817, 823, 832, 839, 845, 852, 861, 868, 874, 881, 1047, 1052, 1057, 1062, and 1067; (ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 6, 19, 27, 35, 45, 52, 56, 62, 69, 76, 83, 90, 109, 116, 123, 134, 142, 149, 156, 163, 169, 176, 183, 196, 209, 216, 223, 236, 273, 319, 328, 630, 776, 782, 789, 798, 804, 811, 818, 824, 833, 840, 846, 853, 862, 869, 875, 882, 1048, 1053, 1058, 1063, and 1068; and (iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 7, 13, 20, 28, 36, 40, 46, 53, 63, 70, 77, 84, 91, 97, 103, 110, 117, 124,128, 135, 143, 150, 157, 164, 170, 177, 184, 190, 197, 203, 210, 217, 224, 230, 237, 241, 244, 248, 253,257, 259, 261, 263, 265, 267, 269, 271, 274, 276, 278, 281, 297, 320, 322, 327, 330, 332, 631, 765, 767,769, 774, 783, 790, 793, 799, 805, 812, 819, 825, 834, 841, 847, 854, 857, 863, 870, 876, 883, 886, 1049,1054, 1059, 1064, and 1069; and (b) VH2 comprises: (i) a CDR1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 5, 12, 18, 26, 34, 44, 51, 61, 68, 75, 82, 89, 96, 102, 108, 115, 122, 133, 141, 148, 155, 162, 175, 182, 189, 195, 202, 208, 215, 222, 229, 235, 318, 629, 773, 781, 788, 797, 803, 810, 817, 823, 832, 839, 845, 852, 861, 868, 874, 881, 1047, 1052, 1057, 1062, and 1067; (ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 6, 19, 27, 35, 45, 52, 56, 62, 69, 76, 83, 90, 109, 116, 123, 134, 142, 149, 156, 163, 169, 176, 183, 196, 209, 216, 223, 236, 273, 319, 328, 630, 776, 782, 789, 798, 804, 811, 818, 824, 833, 840, 846, 853, 862, 869, 875, 882, 1048, 1053, 1058, 1063, and 1068; and (iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 7, 13, 20, 28, 36, 40, 46, 53, 63, 70, 77, 84, 91, 97, 103, 110, 117, 124,128, 135, 143, 150, 157, 164, 170, 177, 184, 190, 197, 203, 210, 217, 224, 230, 237, 241, 244, 248, 253,257, 259, 261, 263, 265, 267, 269, 271, 274, 276, 278, 281, 297, 320, 322, 327, 330, 332, 631, 765, 767,769, 774, 783, 790, 793, 799, 805, 812, 819, 825, 834, 841, 847, 854, 857, 863, 870, 876, 883, 886, 1049,1054, 1059, 1064, and 1069.

[0096] In some aspects, (a) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any oneof SEQ ID NOs: 8, 14, 21, 22, 29, 37, 47, 54, 57, 64, 71, 78, 85, 92, 98, 104, 111, 118, 125, 129, 136, 137, 144, 151, 158, 165, 171, 178, 185, 191, 198, 204, 211, 218, 225, 231, 238, 245, 254, 258, 260, 262, 264, 266, 268, 270, 272, 275, 277, 279, 280, 282, 298, 321, 331, 626, 775, 777, 784, 791, 800, 806, 813, 820, 826, 835, 842, 848, 855, 864, 871, 877, and 884; and (b) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 8, 14, 21, 22, 29, 37, 47, 54, 57, 64, 71, 78, 85, 92, 98, 104,111, 118, 125, 129, 136, 137, 144, 151, 158, 165, 171, 178, 185, 191, 198, 204, 211, 218, 225, 231, 238,245, 254, 258, 260, 262, 264, 266, 268, 270, 272, 275, 277, 279, 280, 282, 298, 321, 331, 626, 775, 777,784, 791, 800, 806, 813, 820, 826, 835, 842, 848, 855, 864, 871, 877, and 884.

[0097] Also provided herein is an antigen binding polypeptide having a structure, from amino -terminus to carboxy-terminus, represented by: VL1-L1-VL2-L2-VL3-L3-CH1; VL1-L1-VL3-L2-VL2-L3-CH1; VL2- L1-VL1-L2-VL3-L3-CH1; VL2-L1-VL3-L2-VL1-L3-CH1; VL3-L1-VL1-L2-VL2-L3-CH1; or VL3-L1- VL2-L2-VL1-L3-CH1; wherein VL1 is a first immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein; VL2 is a second immunoglobulin light chain variable region that specifically binds to a SARS-CoV-2 protein; VL3 is a third immunoglobulin light chain variable region that specifically binds to a SARS-CoV-2 protein; CHI is an immunoglobulin heavy chain constant region 1; and L1-L3 are optional amino acid linkers.

[0098] In some aspects, (a) VL1 comprises: (i) a complementarity determining region (CDR) 1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 1, 9, 15, 23, 30, 41, 48, 55, 58, 65, 72, 79, 86, 93, 99, 105, 112, 119, 130, 138, 145, 152, 159, 166, 172, 179, 186, 192, 199, 205, 212, 219, 226, 232, 324, 627, 770, 778, 785, 794, 801, 807, 814, 827, 836, 849, 858, 865, 878, 1045, 1050, 1055, 1060, and 1065; (ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 2, 31, 628, 1046, 1051, 1056, and 1061, or at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of amino acid sequences AAS, GAS, LGS, GTN, GTN, SAS, SDS, DNT, EVT, DAS, DVT, RNS, DVS, EDS, DDS, KDS, NNN, SYN, WAS, and DAT; and (iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 3, 10, 16, 24, 32, 38, 42, 49, 59, 66, 73, 80, 87, 94, 100, 106, 113, 120, 126, 131, 139,146, 153, 160, 167, 173, 180, 187, 193, 200, 206, 213, 220, 227, 233, 239, 242, 246, 249, 256, 283, 285,287, 288, 290, 292, 294, 296, 301, 304, 306, 309, 311, 313, 316, 325, 326, 329, 764, 766, 768, 771, 779,786, 792, 795, 808, 815, 821, 830, 837, 843, 850, 856, 859, 866, 872, 879, 885, and 1066; (b) VL2 comprises: (i) a complementarity determining region (CDR) 1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 1, 9, 15, 23, 30, 41, 48, 55, 58, 65, 72, 79, 86, 93, 99, 105, 112, 119, 130, 138, 145, 152, 159, 166, 172, 179, 186, 192, 199, 205, 212, 219, 226, 232, 324, 627, 770, 778,785, 794, 801, 807, 814, 827, 836, 849, 858, 865, 878, 1045, 1050, 1055, 1060, and 1065; (ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, atleast 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 2, 31, 628, 1046, 1051, 1056, and 1061, or at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of amino acid sequences AAS, GAS, LGS, GTN, GTN, SAS, SDS, DNT, EVT, DAS, DVT, RNS, DVS, EDS, DDS, KDS, NNN, SYN, WAS, and DAT; and (iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 3, 10, 16, 24, 32, 38, 42, 49, 59, 66, 73, 80, 87, 94, 100, 106, 113, 120, 126, 131, 139, 146, 153, 160, 167, 173, 180, 187, 193, 200, 206, 213, 220, 227, 233, 239, 242, 246, 249, 256, 283, 285, 287, 288, 290, 292, 294, 296, 301, 304, 306, 309, 311, 313, 316, 325, 326, 329, 764, 766, 768, 771, 779, 786, 792, 795, 808, 815, 821, 830, 837, 843, 850, 856, 859, 866, 872, 879, 885, and 1066; and (c) VL3 comprises: (i) a complementarity determining region (CDR) 1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 1, 9, 15, 23, 30, 41, 48, 55, 58, 65, 72, 79, 86, 93, 99, 105, 112, 119, 130, 138, 145, 152, 159, 166, 172, 179, 186, 192, 199, 205, 212, 219, 226, 232, 324, 627, 770, 778, 785, 794, 801, 807, 814, 827, 836, 849, 858, 865, 878, 1045, 1050, 1055, 1060, and 1065; (ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 2, 31, 628, 1046, 1051, 1056, and 1061, or at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of amino acid sequences AAS, GAS, LGS, GTN, GTN, SAS, SDS, DNT, EVT, DAS, DVT, RNS, DVS, EDS, DDS, KDS, NNN, SYN, WAS, and DAT; and (iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 3, 10, 16, 24, 32, 38, 42, 49, 59, 66, 73, 80, 87, 94, 100,106, 113, 120, 126, 131, 139, 146, 153, 160, 167, 173, 180, 187, 193, 200, 206, 213, 220, 227, 233, 239,242, 246, 249, 256, 283, 285, 287, 288, 290, 292, 294, 296, 301, 304, 306, 309, 311, 313, 316, 325, 326,329, 764, 766, 768, 771, 779, 786, 792, 795, 808, 815, 821, 830, 837, 843, 850, 856, 859, 866, 872, 879,885, and 1066.

[0099] In some aspects, (a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 4, 11, 17, 25, 33, 39, 43, 50, 60, 67, 74, 81, 88, 95, 101, 107, 114, 121, 127, 132, 140, 147,154, 161, 168, 174, 181, 188, 194, 201, 207, 214, 221, 228, 234, 240, 243, 247, 250, 251, 252, 255, 284,286, 289, 291, 293, 295, 299, 300, 302, 303, 305, 307, 308, 310, 312, 314, 315, 317, 323, 772, 780, 787,796, 802, 809, 816, 822, 831, 838, 844, 851, 860, 867, 873, 880, and 988; (b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 4, 11, 17, 25, 33, 39, 43, 50, 60, 67, 74, 81, 88, 95, 101, 107, 114, 121, 127, 132, 140, 147, 154, 161, 168, 174, 181, 188, 194, 201, 207, 214, 221, 228, 234, 240, 243, 247, 250, 251, 252, 255, 284, 286, 289, 291, 293, 295, 299, 300, 302, 303, 305, 307, 308, 310, 312, 314, 315, 317, 323, 772, 780, 787, 796, 802, 809, 816, 822, 831, 838, 844, 851, 860, 867, 873, 880, and 988; and (c) VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one ofSEQ ID NOs: 4, 11, 17, 25, 33, 39, 43, 50, 60, 67, 74, 81, 88, 95, 101, 107, 114, 121, 127, 132, 140, 147,154, 161, 168, 174, 181, 188, 194, 201, 207, 214, 221, 228, 234, 240, 243, 247, 250, 251, 252, 255, 284,286, 289, 291, 293, 295, 299, 300, 302, 303, 305, 307, 308, 310, 312, 314, 315, 317, 323, 772, 780, 787,796, 802, 809, 816, 822, 831, 838, 844, 851, 860, 867, 873, 880, and 988.

[0100] Also provided herein is an antigen binding polypeptide having a structure, from amino -terminus to carboxy-terminus, represented by: VH1-L1-VH2-L2-VH3-L3-CL; VH1-L1-VH3-L2-VH2-L3-CL; VH2- L1-VH1-L2-VH3-L3-CL; VH2-L1-VH3-L2-VH1-L3-CL; VH3-L1-VH1-L2-VH2-L3-CL; or VH3-L1- VH2-L2-VH1-L3-CL; wherein VH1 is a first immunoglobulin heavy chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein; VH2 is a second immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; VH3 is a third immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; CL is an immunoglobulin light chain constant region; and L1-L3 are optional amino acid linkers.

[0101] In some aspects, (a) VH1 comprises: (i) a CDR1 having an amino acid sequence that is at least65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 5, 12, 18, 26, 34, 44, 51, 61, 68, 75, 82, 89, 96, 102, 108, 115, 122, 133, 141, 148, 155, 162, 175, 182, 189, 195, 202, 208, 215, 222, 229, 235, 318, 629, 773, 781, 788,797, 803, 810, 817, 823, 832, 839, 845, 852, 861, 868, 874, 881, 1047, 1052, 1057, 1062, and 1067; (ii) aCDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 6, 19, 27, 35, 45, 52, 56, 62, 69, 76, 83, 90, 109, 116, 123, 134, 142, 149, 156, 163, 169, 176, 183, 196, 209, 216, 223, 236, 273, 319, 328, 630, 776, 782, 789, 798, 804, 811, 818, 824, 833, 840, 846, 853, 862, 869, 875, 882, 1048, 1053, 1058, 1063, and 1068; and (iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 7, 13, 20, 28, 36, 40, 46, 53, 63, 70, 77, 84, 91, 97, 103, 110, 117, 124,128, 135, 143, 150, 157, 164, 170, 177, 184, 190, 197, 203, 210, 217, 224, 230, 237, 241, 244, 248, 253,257, 259, 261, 263, 265, 267, 269, 271, 274, 276, 278, 281, 297, 320, 322, 327, 330, 332, 631, 765, 767,769, 774, 783, 790, 793, 799, 805, 812, 819, 825, 834, 841, 847, 854, 857, 863, 870, 876, 883, 886, 1049,1054, 1059, 1064, and 1069; (b) VH2 comprises: (i) a CDR1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 5, 12, 18, 26, 34, 44, 51, 61, 68, 75, 82, 89, 96, 102, 108, 115, 122, 133, 141, 148, 155, 162, 175, 182, 189, 195, 202, 208, 215, 222, 229, 235, 318, 629, 773, 781, 788, 797, 803, 810, 817, 823, 832, 839, 845, 852, 861, 868, 874, 881, 1047, 1052, 1057, 1062, and 1067; (ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 6, 19, 27, 35, 45, 52, 56, 62, 69, 76, 83, 90, 109, 116, 123, 134, 142, 149, 156, 163, 169, 176, 183, 196, 209, 216, 223, 236, 273, 319, 328, 630, 776, 782, 789, 798, 804, 811, 818, 824, 833, 840, 846, 853, 862, 869, 875, 882, 1048, 1053, 1058, 1063, and 1068; and (iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 7, 13, 20, 28, 36, 40, 46, 53, 63, 70, 77, 84, 91, 97, 103, 110, 117, 124,128, 135, 143, 150, 157, 164, 170, 177, 184, 190, 197, 203, 210, 217, 224, 230, 237, 241, 244, 248, 253, 257, 259, 261, 263, 265, 267, 269, 271, 274, 276, 278, 281, 297, 320, 322, 327, 330, 332, 631, 765, 767, 769, 774, 783, 790, 793, 799, 805, 812, 819, 825, 834, 841, 847, 854, 857, 863, 870, 876, 883, 886, 1049, 1054, 1059, 1064, and 1069; and (c) VH3 comprises: (i) a CDR1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 5, 12, 18, 26, 34, 44, 51, 61, 68, 75, 82, 89, 96, 102, 108, 115, 122, 133, 141, 148, 155, 162, 175, 182, 189, 195, 202, 208, 215, 222, 229, 235, 318, 629, 773, 781, 788, 797, 803, 810, 817, 823, 832, 839, 845, 852, 861, 868, 874, 881, 1047, 1052, 1057, 1062, and 1067; (ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 6, 19, 27, 35, 45, 52, 56, 62, 69, 76, 83, 90, 109, 116, 123, 134, 142, 149, 156, 163, 169, 176, 183, 196, 209, 216, 223, 236, 273, 319, 328, 630, 776, 782, 789, 798, 804, 811, 818, 824, 833, 840, 846, 853, 862, 869, 875, 882, 1048, 1053, 1058, 1063, and 1068; and (iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 7, 13, 20, 28, 36, 40, 46, 53, 63, 70, 77, 84, 91, 97, 103, 110, 117, 124,128, 135, 143, 150, 157, 164, 170, 177, 184, 190, 197, 203, 210, 217, 224, 230, 237, 241, 244, 248, 253,257, 259, 261, 263, 265, 267, 269, 271, 274, 276, 278, 281, 297, 320, 322, 327, 330, 332, 631, 765, 767,769, 774, 783, 790, 793, 799, 805, 812, 819, 825, 834, 841, 847, 854, 857, 863, 870, 876, 883, 886, 1049,1054, 1059, 1064, and 1069.

[0102] In some aspects, (a) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 8, 14, 21, 22, 29, 37, 47, 54, 57, 64, 71, 78, 85, 92, 98, 104, 111, 118, 125, 129, 136, 137, 144, 151, 158, 165, 171, 178, 185, 191, 198, 204, 211, 218, 225, 231, 238, 245, 254, 258, 260, 262, 264, 266, 268, 270, 272, 275, 277, 279, 280, 282, 298, 321, 331, 626, 775, 777, 784, 791, 800, 806, 813, 820, 826, 835, 842, 848, 855, 864, 871, 877, and 884; (b) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 8, 14, 21, 22, 29, 37, 47, 54, 57, 64, 71, 78, 85, 92, 98, 104,111, 118, 125, 129, 136, 137, 144, 151, 158, 165, 171, 178, 185, 191, 198, 204, 211, 218, 225, 231, 238,245, 254, 258, 260, 262, 264, 266, 268, 270, 272, 275, 277, 279, 280, 282, 298, 321, 331, 626, 775, 777,784, 791, 800, 806, 813, 820, 826, 835, 842, 848, 855, 864, 871, 877, and 884; and (c) VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 8, 14, 21, 22, 29, 37, 47, 54, 57, 64, 71, 78, 85, 92, 98, 104, 111, 118, 125, 129, 136, 137, 144, 151, 158, 165, 171, 178, 185, 191, 198, 204, 211, 218, 225, 231, 238, 245, 254, 258, 260, 262, 264, 266, 268, 270, 272, 275, 277, 279, 280, 282, 298, 321, 331, 626, 775, 777, 784, 791, 800, 806, 813, 820, 826, 835, 842, 848, 855, 864, 871, 877, and 884.

[0103] In some aspects, the antigen binding polypeptide further comprises an Fc region at the carboxyterminus. In some aspects, the Fc region comprises an immunoglobulin heavy chain constant region 2 (CH2) and / or an immunoglobulin heavy chain constant region 3 (CH3). In some aspects, the Fc region further comprises an immunoglobulin hinge. In some aspects, the Fc region comprises an amino acidsequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 376-380. In some aspects, the Fc region comprises one or more half-life extension amino acid substitutions. In some aspects, the one or more halflife extension amino acid substitutions comprise one or more of amino acid substitutions M428L, N434A, N434S, L234F, L235E, P33 IS, M252Y, S254T, or T256E, or equivalent thereof, based on the EU numbering scheme. In some aspects, the one or more half-life extension amino acid substitutions comprise amino acid substitutions: (i) L234A and L235A (LA); (ii) M428L and N434S (LS); (iii) L234F and L235E; (iv) L234F, L235E, and P33 IS (TM); and / or (v) M252Y, S254T, and T256E (YTE); or equivalent thereof, based on the EU numbering scheme.

[0104] Also provided herein is an antigen binding polypeptide complex comprising a first polypeptide and a second polypeptide, wherein the first polypeptide has a structure, from amino-terminus to carboxyterminus, represented by: VL1-L1-CL-L2-VL2-L3-VH2-L4-VH1-L5-CH1; VL1-L1-CL-L2-VH2-L3-VL2- L4-VH1-L5-CH1; VL1-L1-CH1-L2-VL2-L3-VH2-L4-VH1-L5-CL; VL1-L1-CH1-L2-VH2-L3-VL2-L4- VH 1 -L5-CL; VH 1 -L 1-CL-L2-VL2-L3 -VH2-L4-VL 1 -L5-CH 1 ; VH 1 -L 1 -CL-L2-VH2-L3 -VL2-L4-VL 1 - L5-CH1; VH1-L1-CH1-L2-VL2-L3-VH2-L4-VL1-L5-CL; VH1-L1-CH1-L2-VH2-L3-VL2-L4-VL1-L5- CL; VL2-L1-CL-L2-VL1-L3-VH1-L4-VH2-L5-CH1; VL2-L1-CL-L2-VH1-L3-VL1-L4-VH2-L5-CH1; VL2-L1-CH1-L2-VL1-L3-VH1-L4-VH2-L5-CL; VL2-L1-CH1-L2-VH1-L3-VL1-L4-VH2-L5-CL; VH2- L 1-CL-L2-VL 1 -L3 -VH 1 -L4-VL2-L5-CH 1 ; VH2-L 1 -CL-L2-VH 1-L3 -VL 1 -L4-VL2-L5-CH 1 ; VH2-L 1 - CH1-L2-VL1-L3-VH1-L4-VL2-L5-CL; or VH2-L1-CH1-L2-VH1-L3-VL1-L4-VL2-L5-CL; wherein the second polypeptide has a structure, from amino-terminus to carboxy -terminus, represented by: VL3-L6-CL- L7-VL4-L8-VH4-L9-VH3-L10-CH1; VL3-L6-CL-L7-VH4-L8-VL4-L9-VH3-L10-CH1; VL3-L6-CH1-L7- VL4-L8-VH4-L9-VH3-L10-CL; VL3-L6-CH1-L7-VH4-L8-VL4-L9-VH3-L10-CL; VH3-L6-CL-L7-VL4- L8-VH4-L9-VL3-L10-CH1; VH3-L6-CL-L7-VH4-L8-VL4-L9-VL3-L10-CH1; VH3-L6-CH1-L7-VL4-L8- VH4-L9-VL3-L10-CL; VH3-L6-CH1-L7-VH4-L8-VL4-L9-VL3-L10-CL; VL4-L6-CL-L7-VL3-L8-VH3- L9-VH4-L10-CH1; VL4-L6-CL-L7-VH3-L8-VL3-L9-VH4-L10-CH1; VL4-L6-CH1-L7-VL3-L8-VH3-L9- VH4-L10-CL; VL4-L6-CH1-L7-VH3-L8-VL3-L9-VH4-L10-CL; VH4-L6-CL-L7-VL3-L8-VH3-L9-VL4- L10-CH1; VH4-L6-CL-L7-VH3-L8-VL3-L9-VL4-L10-CH1; VH4-L6-CH1-L7-VL3-L8-VH3-L9-VL4- L10-CL; or VH4-L6-CH1-L7-VH3-L8-VL3-L9-VL4-L10-CL; and wherein: VL1 is a first immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (S ARS-CoV-2) protein; VL2 is a second immunoglobulin light chain variable region that specifically binds to a S ARS-CoV-2 protein; VL3 is a third immunoglobulin light chain variable region that specifically binds to a SARS-CoV-2 protein; VL4 is a fourth immunoglobulin light chain variable region that specifically binds to a SARS-CoV-2 protein; VH1 is a first immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; VH2 is a second immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; VH3 is a third immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; VH4 is a fourth immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; CL is an immunoglobulin light chain constant region; CHI is an immunoglobulin heavy chain constant region 1; and LI -L10 are optional amino acid linkers.

[0105] Also provided herein is an antigen binding polypeptide complex comprising a first polypeptide and a second polypeptide, wherein the first polypeptide has a structure, from amino-terminus to carboxyterminus, represented by: VL1-CL-L1-VL2-L2-VH2-L3-VH1-CH1; VL1-CL-L1-VH2-L2-VL2-L3-VH1- CH1; VL1-CH1-L1-VL2-L2-VH2-L3-VH1-CL; VL1-CH1-L1-VH2-L2-VL2-L3-VH1-CL; VH1-CL-L1- VL2-L2-VH2-L3 -VL 1 -CH 1 ; VH 1 -CL-L 1 -VH2-L2-VL2-L3 -VL 1 -CH 1 ; VH 1 -CH 1 -L 1-VL2-L2-VH2-L3 - VL1-CL; VH1-CH1-L1-VH2-L2-VL2-L3-VL1-CL; VL2-CL-L1-VL1-L2-VH1-L3-VH2-CH1; VL2-CL- L 1-VH 1 -L2-VL 1 -L3 -VH2-CH 1 ; VL2-CH 1 -L 1 -VL 1 -L2-VH 1-L3 -VH2-CL; VL2-CH 1 -L 1 -VH 1 -L2-VL 1 - L3-VH2-CL; VH2-CL-L1-VL1-L2-VH1-L3-VL2-CH1; VH2-CL-L1-VH1-L2-VL1-L3-VL2-CH1; VH2- CH1-L1-VL1-L2-VH1-L3-VL2-CL; or VH2-CH1-L1-VH1-L2-VL1-L3-VL2-CL; wherein the second polypeptide has a structure, from amino-terminus to carboxy-terminus, represented by: VL3-CL-L4-VL4- L5-VH4-L6-VH3-CH1; VL3-CL-L4-VH4-L5-VL4-L6-VH3-CH1; VL3-CH1-L4-VL4-L5-VH4-L6-VH3- CL; VL3-CH1-L4-VH4-L5-VL4-L6-VH3-CL; VH3-CL-L4-VL4-L5-VH4-L6-VL3-CH1; VH3-CL-L4- VH4-L5-VL4-L6-VL3 -CH 1 ; VH3 -CH 1 -L4-VL4-L5-VH4-L6-VL3 -CL; VH3 -CH 1 -L4-VH4-L5-VL4-L6- VL3-CL; VL4-CL-L4-VL3-L5-VH3-L6-VH4-CH1; VL4-CL-L4-VH3-L5-VL3-L6-VH4-CH1; VL4-CH1- L4-VL3-L5-VH3-L6-VH4-CL; VL4-CH1-L4-VH3-L5-VL3-L6-VH4-CL; VH4-CL-L4-VL3-L5-VH3-L6- VL4-CH1; VH4-CL-L4-VH3-L5-VL3-L6-VL4-CH1; VH4-CH1-L4-VL3-L5-VH3-L6-VL4-CL; or VH4- CH1-L4-VH3-L5-VL3-L6-VL4-CL; and wherein: VL1 is a first immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein; VL2 is a second immunoglobulin light chain variable region that specifically binds to a SARS-CoV-2 protein; VL3 is a third immunoglobulin light chain variable region that specifically binds to a SARS-CoV-2 protein; VL4 is a fourth immunoglobulin light chain variable region that specifically binds to a SARS-CoV- 2 protein; VH1 is a first immunoglobulin heavy chain variable region that specifically binds to a SARS- CoV-2 protein; VH2 is a second immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; VH3 is a third immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; VH4 is a fourth immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein; CL is an immunoglobulin light chain constant region; CHI is an immunoglobulin heavy chain constant region 1; and L1-L6 are amino acid linkers.

[0106] In some aspects, VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

[0107] In some aspects, VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO:11; VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; and VH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

[0108] In some aspects, VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325; VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; VH1comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332; VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

[0109] In some aspects, VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25; VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29; VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; and VH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

[0110] In some aspects, VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325; VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1 or 324, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 2 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 3; VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 30, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 31 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 32, 38, or 326; VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332; VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 5, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 7; VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acidsequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 34, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 35, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 36, 40, or 327.

[0111] In some aspects, VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25; VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 4; VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 33 or 39; VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29; VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 8; VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; and VH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 37.

[0112] In some aspects, VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; VL3 comprises a CDR1 having anamino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

[0113] In some aspects, VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; VL3 comprises anamino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; and VH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

[0114] In some aspects, VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 152 or 1045, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1046 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, atleast 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 153 or 766; VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 155 or 1047, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 156 or 1048, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 157, 767, or 1049.

[0115] In some aspects, VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 154; VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; andVH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 158.

[0116] In some aspects, VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764; VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical toSEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

[0117] In some aspects, VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147; VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; and VH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

[0118] In some aspects, VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764; VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 152 or 1045, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1046 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 153 or 766; VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 155 or 1047, a CDR2 having an amino acid sequence atleast 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 156 or 1048, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 157, 767, or 1049.

[0119] In some aspects, VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147; VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 154; VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; and VH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 158.

[0120] In some aspects, VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764; VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or100% identical to SEQ ID NO: 16; VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631.

[0121] In some aspects, VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147; VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; VH1 comprises an amino acid sequence that is at least 65%, atleast 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; and VH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626.

[0122] In some aspects, VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764; VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 152 or 1045, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1046 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 153 or 766; VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least7Q° / o, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 155 or 1047, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 156 or 1048, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 157, 767, or 1049; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631.

[0123] In some aspects, VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147; VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 154; VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 158; and VH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626.

[0124] In some aspects, VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764; VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, atleast 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054.

[0125] In some aspects, VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147; VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; and VH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151.

[0126] In some aspects, VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; VL3 comprises a CDR1 having anamino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764; VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

[0127] In some aspects, VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147; VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; and VH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

[0128] In some aspects, VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%,at least 99%, or 100% identical to SEQ ID NO: 146 or 764; VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054.

[0129] In some aspects, VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147; VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; and VH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151.

[0130] In some aspects, VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764; VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; VH3comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

[0131] In some aspects, VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147; VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; and VH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

[0132] In some aspects, VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764; VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054.

[0133] In some aspects, VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147; VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; and VH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151.

[0134] In some aspects, VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764; VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ IDNO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631.

[0135] In some aspects, VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147; VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; and VH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626.

[0136] In some aspects, VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764; VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%,at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054.

[0137] In some aspects, VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147; VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; and VH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151.

[0138] In some aspects, VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, atleast 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764; VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, atleast 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631.

[0139] In some aspects, VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147; VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; and VH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626.

[0140] In some aspects, VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764; VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66; VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

[0141] In some aspects, VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147; VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67; VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or100% identical to SEQ ID NO: 14; VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; and VH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

[0142] In some aspects, VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764; VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at leas...

Claims

1. WHAT IS CLAIMED IS:

1. An antigen binding polypeptide having a structure, from amino -terminus to carboxy-terminus, represented by:VL 1 -L 1 -CL-L2-VL2-L3-VH2-L4-VH 1 -L5-CH 1 ;VL 1 -L 1 -CL-L2-VH2-L3 -VL2-L4-VH 1-L5-CH 1 ;VL 1 -L 1 -CH 1 -L2-VL2-L3 -VH2-L4-VH 1 -L5-CL;VL 1 -L 1 -CH 1 -L2-VH2-L3 -VL2-L4-VH 1 -L5-CL;VH1-L1-CL-L2-VL2-L3-VH2-L4-VL1-L5-CH1;VH 1 -L 1 -CL-L2-VH2-L3 -VL2-L4-VL 1 -L5-CH 1 ;VH 1 -L 1-CH 1 -L2-VL2-L3-VH2-L4-VL 1 -L5-CL;VH 1 -L 1 -CH 1 -L2-VH2-L3 -VL2-L4-VL 1-L5-CL;VL2-L 1 -CL-L2-VL 1 -L3-VH 1 -L4-VH2-L5-CH 1 ;VL2-L 1 -CL-L2-VH 1 -L3 -VL 1 -L4-VH2-L5-CH 1 ;VL2-L 1 -CH 1 -L2-VL 1 -L3 -VH 1 -L4-VH2-L5-CL;VL2-L 1 -CH 1 -L2-VH 1 -L3 -VL 1 -L4-VH2-L5-CL;VH2-L1-CL-L2-VL1-L3-VH1-L4-VL2-L5-CH1;VH2-L 1 -CL-L2-VH 1-L3 -VL 1 -L4-VL2-L5-CH 1 ;VH2-L1-CH1-L2-VL1-L3-VH1-L4-VL2-L5-CL; orVH2-L 1 -CH 1 -L2-VH 1 -L3 -VL 1 -L4-VL2-L5-CL; wherein:VL1 is a first immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein;VL2 is a second immunoglobulin light chain variable region that specifically binds to a SARS- CoV-2 protein;VH1 is a first immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV- 2 protein;VH2 is a second immunoglobulin heavy chain variable region that specifically binds to a SARS- CoV-2 protein;CL is an immunoglobulin light chain constant region;CHI is an immunoglobulin heavy chain constant region 1; and L1-L5 are optional amino acid linkers.

2. An antigen binding polypeptide having a structure, from amino -terminus to carboxy-terminus, represented by:VL 1 -CL-L 1 -VL2-L2-VH2-L3 -VH 1 -CH 1 ;VL 1 -CL-L 1 -VH2-L2-VL2-L3 - VH 1 -CH 1 ;VL 1 -CH 1 -L 1 -VL2-L2-VH2-L3 -VH 1-CL;VL 1 -CH 1 -L 1 -VH2-L2-VL2-L3 -VH 1 -CL;VH 1 -CL-L 1 -VL2-L2-VH2-L3 -VL 1 -CH 1 ;VH 1 -CL-L 1 -VH2-L2-VL2-L3 -VL 1 -CH 1 ;VH 1 -CH 1 -L 1 -VL2-L2-VH2-L3 -VL 1 -CL;VH 1 -CH 1 -L 1 -VH2-L2-VL2-L3 -VL 1 -CL;VL2-CL-L 1 -VL 1 -L2-VH 1 -L3 -VH2-CH 1 ;VL2-CL-L 1 -VH 1-L2-VL 1 -L3 -VH2-CH 1 ;VL2-CH 1 -L 1 -VL 1 -L2-VH 1-L3 -VH2-CL;VL2-CH 1 -L 1 -VH 1 -L2-VL 1 -L3 -VH2-CL;VH2-CL-L 1 -VL 1 -L2-VH 1 -L3 -VL2-CH 1 ;VH2-CL-L 1 -VH 1 -L2-VL 1 -L3 -VL2-CH 1 ;VH2-CH1-L1-VL1-L2-VH1-L3-VL2-CL; orVH2-CH 1 -L 1 -VH 1 -L2-VL 1 -L3 -VL2-CL; wherein:VL1 is a first immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein;VL2 is a second immunoglobulin light chain variable region that specifically binds to a SARS- CoV-2 protein;VH1 is a first immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV- 2 protein;VH2 is a second immunoglobulin heavy chain variable region that specifically binds to a SARS- CoV-2 protein;CL is an immunoglobulin light chain constant region;CHI is an immunoglobulin heavy chain constant region 1; andL1-L3 are amino acid linkers.

3. An antigen binding polypeptide having a structure, from amino -terminus to carboxy-terminus, represented by:VL 1 -L 1 -VH 1-L2-VL2-L3 -CL-L4-VH2-L5-CH 1 ;VL 1 -L 1 -VH 1-L2-VL2-L3 -CH 1-L4-VH2-L5-CL;VL 1 -L 1 -VH 1-L2-VH2-L3 -CL-L4-VL2-L5-CH 1 ;VL 1 -L 1 -VH 1-L2-VH2-L3 -CH 1 -L4-VL2-L5-CL;VL 1 -L 1 -VL2-L2-VH 1 -L3 -CL-L4-VH2-L5-CH 1 ;VL 1 -L 1 -VL2-L2-VH 1 -L3 -CH 1 -L4-VH2-L5-CL;VL 1 -L 1 -VH2-L2-VH 1-L3 -CL-L4-VL2-L5-CH 1 ;VL 1 -L 1 -VH2-L2-VH 1-L3 -CH 1 -L4-VL2-L5-CL;VH 1 -L 1 -VL 1 -L2-VL2-L3 -CL-L4-VH2-L5-CH 1 ;VH 1 -L 1 -VL 1 -L2-VL2-L3 -CH 1-L4-VH2-L5-CL;VH 1 -L 1-VL 1 -L2-VH2-L3 -CL-L4-VL2-L5-CH 1 ;VH 1 -L 1-VL 1 -L2-VH2-L3 -CH 1 -L4-VL2-L5-CL;VH1-L1-VL2-L2-VL1-L3-CL-L4-VH2-L5-CH1;VH 1 -L 1 -VL2-L2-VL 1 -L3 -CH 1-L4-VH2-L5-CL;VH1-L1-VH2-L2-VL1-L3-CL-L4-VL2-L5-CH1;VH 1 -L 1-VH2-L2-VL 1 -L3 -CH 1 -L4-VL2-L5-CL;VL2-L1-VL1-L2-VH2-L3-CL-L4-VH1-L5-CH1;VL2-L 1 -VL 1 -L2-VH2-L3 -CH 1 -L4-VH 1 -L5-CL;VL2-L 1 -VH 1-L2-VH2-L3 -CL-L4-VL 1 -L5-CH 1 ;VL2-L 1 -VH 1-L2-VH2-L3 -CH 1 -L4-VL 1 -L5-CL;VL2-L 1 -VH2-L2-VL 1 -L3 -CL-L4-VH 1 -L5-CH 1 ;VL2-L 1 -VH2-L2-VL 1 -L3 -CH 1-L4-VH 1-L5-CL;VL2-L 1 -VH2-L2-VH 1-L3 -CL-L4-VL 1 -L5-CH 1 ;VL2-L 1 -VH2-L2-VH 1-L3 -CH 1 -L4-VL 1 -L5-CL;VH2-L 1 -VL 1 -L2-VL2-L3 -CL-L4-VH 1 -L5-CH 1 ;VH2-L1-VL1-L2-VL2-L3-CH1-L4-VH1-L5-CL;VH2-L1-VH1-L2-VL2-L3-CL-L4-VL1-L5-CH1;VH2-L 1-VH 1 -L2-VL2-L3 -CH 1 -L4-VL 1 -L5-CL;VH2-L1-VL2-L2-VL1-L3-CL-L4-VH1-L5-CH1;VH2-L 1 -VL2-L2-VL 1 -L3 -CH 1-L4-VH 1-L5-CL;VH2-L1-VL2-L2-VH1-L3-CL-L4-VL1-L5-CH1; orVH2-L 1-VL2-L2-VH 1 -L3 -CH 1-L4-VL 1 -L5-CL; wherein:VL1 is a first immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein;VL2 is a second immunoglobulin light chain variable region that specifically binds to a SARS- CoV-2 protein;VH1 is a first immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV- 2 protein;VH2 is a second immunoglobulin heavy chain variable region that specifically binds to a SARS- CoV-2 protein;CL is an immunoglobulin light chain constant region;CHI is an immunoglobulin heavy chain constant region 1; andL1-L5 are optional amino acid linkers.

4. An antigen binding polypeptide having a structure, from amino -terminus to carboxy-terminus, represented by:VL 1 -L 1 -CL-L2-VH 1 -L3 -CH 1 -L4-VL2-L5-VH2;VL 1 -L 1 -CL-L2-VH 1 -L3 -CH 1 -L4-VH2-L5-VL2;VL 1 -L 1 -CL-L2-VL2-L3-CH 1 -L4-VH 1 -L5-VH2;VL 1 -L 1 -CL-L2-VH2-L3 -CH 1 -L4-VH 1 -L5-VL2;VL 1 -L 1 -CH 1 -L2-VH 1 -L3 -CL-L4-VL2-L5-VH2;VL 1 -L 1 -CH 1 -L2-VH 1 -L3 -CL-L4-VH2-L5-VL2;VL 1 -L 1 -CH 1 -L2-VL2-L3 -CL-L4-VH 1 -L5-VH2;VL 1 -L 1 -CH 1 -L2-VH2-L3 -CL-L4-VH 1-L5-VL2;VH 1 -L 1 -CL-L2-VL 1 -L3 -CH 1 -L4-VL2-L5-VH2;VH 1 -L 1 -CL-L2-VL 1 -L3 -CH 1 -L4-VH2-L5-VL2;VH 1 -L 1 -CL-L2-VL2-L3 -CH 1 -L4-VL 1 -L5-VH2;VH 1 -L 1 -CL-L2-VH2-L3-CH 1 -L4-VL 1-L5-VL2;VH 1 -L 1-CH 1 -L2-VL 1 -L3-CL-L4-VL2-L5-VH2;VH 1 -L 1-CH 1 -L2-VL 1 -L3 -CL-L4-VH2-L5-VL2;VH 1 -L 1-CH 1 -L2-VL2-L3-CL-L4-VL 1 -L5-VH2;VH 1 -L 1 -CH 1 -L2- VH2-L3 -CL-L4-VL 1 -L5 - VL2 ;VL2-L 1 -CL-L2-VL 1 -L3-CH 1 -L4-VH2-L5-VH 1 ;VL2-L 1 -CL-L2-VH 1 -L3 -CH 1 -L4-VH2-L5-VL 1 ;VL2-L1-CL-L2-VH2-L3-CH1-L4-VL1-L5-VH1;VL2-L 1 -CL-L2-VH2-L3 -CH 1 -L4-VH 1 -L5-VL 1 ;VL2-L 1 -CH 1 -L2-VL 1 -L3 -CL-L4-VH2-L5-VH 1 ;VL2-L 1 -CH 1 -L2-VH 1 -L3 -CL-L4-VH2-L5-VL 1 ;VL2-L 1 -CH 1 -L2-VH2-L3 -CL-L4-VL 1 -L5-VH 1 ;VL2-L 1 -CH 1 -L2-VH2-L3 -CL-L4-VH 1-L5-VL 1 ;VH2-L 1 -CL-L2-VL 1 -L3 -CH 1 -L4-VL2-L5-VH 1 ;VH2-L 1 -CL-L2-VH1 -L3-CH 1 -L4-VL2-L5-VL 1 ;VH2-L 1 -CL-L2-VL2-L3 -CH 1 -L4-VL 1 -L5-VH 1 ;VH2-L 1 -CL-L2-VL2-L3 -CH 1 -L4-VH 1 -L5-VL 1 ;VH2-L 1-CH 1 -L2-VL 1 -L3-CL-L4-VL2-L5-VH 1 ;VH2-L 1-CH 1 -L2-VH 1 -L3 -CL-L4-VL2-L5-VL 1 ;VH2-L 1-CH 1 -L2-VL2-L3 -CL-L4-VL 1 -L5-VH 1 ; orVH2-L1-CH1-L2-VL2-L3-CL-L4-VH1-L5-VL1; wherein:VL1 is a first immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein;VL2 is a second immunoglobulin light chain variable region that specifically binds to a SARS- CoV-2 protein;VH1 is a first immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV- 2 protein;VH2 is a second immunoglobulin heavy chain variable region that specifically binds to a SARS- CoV-2 protein;CL is an immunoglobulin light chain constant region;CHI is an immunoglobulin heavy chain constant region 1; andL1-L5 are optional amino acid linkers.

5. The antigen binding polypeptide of any one of claims 1-4, wherein:(a) VL1 comprises:(i) a complementarity determining region (CDR) 1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 1, 9, 15, 23, 30, 41, 48, 55, 58, 65, 72, 79, 86, 93, 99, 105, 112, 119, 130, 138, 145, 152, 159, 166, 172, 179, 186, 192, 199, 205, 212, 219, 226, 232, 324, 627, 770, 778, 785, 794, 801, 807, 814, 827, 836, 849, 858, 865, 878, 1045, 1050, 1055, 1060, and 1065;(ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 2, 31, 628, 1046, 1051, 1056, and 1061, or at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of amino acid sequences AAS, GAS, LGS, GTN, GTN, SAS, SDS, DNT, EVT, DAS, DVT, RNS, DVS, EDS, DDS, KDS, NNN, SYN, WAS, and DAT; and(iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 3, 10, 16, 24, 32, 38, 42, 49, 59, 66, 73, 80, 87, 94, 100, 106, 113, 120, 126, 131, 139, 146,153, 160, 167, 173, 180, 187, 193, 200, 206, 213, 220, 227, 233, 239, 242, 246, 249, 256, 283, 285, 287,288, 290, 292, 294, 296, 301, 304, 306, 309, 311, 313, 316, 325, 326, 329, 764, 766, 768, 771, 779, 786,792, 795, 808, 815, 821, 830, 837, 843, 850, 856, 859, 866, 872, 879, 885, and 1066;(b) VH1 comprises(i) a CDR1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 5, 12, 18, 26, 34, 44, 51, 61, 68, 75, 82, 89, 96, 102, 108, 115, 122, 133, 141, 148, 155, 162, 175, 182, 189, 195, 202, 208, 215, 222, 229, 235, 318, 629, 773, 781, 788, 797, 803, 810, 817, 823, 832, 839, 845, 852, 861, 868, 874, 881, 1047, 1052, 1057, 1062, and 1067;(ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 6, 19, 27, 35, 45, 52, 56, 62, 69, 76, 83, 90, 109, 116, 123, 134, 142, 149, 156, 163, 169, 176, 183, 196, 209, 216, 223, 236, 273, 319, 328, 630, 776, 782, 789, 798, 804, 811, 818, 824, 833, 840, 846, 853, 862, 869, 875, 882, 1048, 1053, 1058, 1063, and 1068; and(iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 7, 13, 20, 28, 36, 40, 46, 53, 63, 70, 77, 84, 91, 97, 103, 110, 117, 124, 128, 135, 143, 150, 157, 164, 170, 177, 184, 190, 197, 203, 210, 217, 224, 230, 237, 241, 244, 248, 253, 257, 259, 261, 263,265, 267, 269, 271, 274, 276, 278, 281, 297, 320, 322, 327, 330, 332, 631, 765, 767, 769, 774, 783, 790,793, 799, 805, 812, 819, 825, 834, 841, 847, 854, 857, 863, 870, 876, 883, 886, 1049, 1054, 1059, 1064, and 1069;(c) VL2 comprises(i) a complementarity determining region (CDR) 1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 1, 9, 15, 23, 30, 41, 48, 55, 58, 65, 72, 79, 86, 93, 99, 105, 112, 119, 130, 138, 145, 152, 159, 166, 172, 179, 186, 192, 199, 205, 212, 219, 226, 232, 324, 627, 770, 778, 785, 794, 801, 807, 814, 827, 836, 849, 858, 865, 878, 1045, 1050, 1055, 1060, and 1065;(ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 2, 31, 628, 1046, 1051, 1056, and 1061, or at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of amino acid sequences AAS, GAS, LGS, GTN, GTN, SAS, SDS, DNT, EVT, DAS, DVT, RNS, DVS, EDS, DDS, KDS, NNN, SYN, WAS, and DAT; and(iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 3, 10, 16, 24, 32, 38, 42, 49, 59, 66, 73, 80, 87, 94, 100, 106, 113, 120, 126, 131, 139, 146,153, 160, 167, 173, 180, 187, 193, 200, 206, 213, 220, 227, 233, 239, 242, 246, 249, 256, 283, 285, 287,288, 290, 292, 294, 296, 301, 304, 306, 309, 311, 313, 316, 325, 326, 329, 764, 766, 768, 771, 779, 786,792, 795, 808, 815, 821, 830, 837, 843, 850, 856, 859, 866, 872, 879, 885, and 1066; and(d) VH2 comprises(i) a CDR1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 5, 12, 18, 26, 34, 44, 51, 61, 68, 75, 82, 89, 96, 102, 108, 115, 122, 133, 141, 148, 155, 162, 175, 182, 189, 195, 202, 208, 215, 222, 229, 235, 318, 629, 773, 781, 788, 797, 803, 810, 817, 823, 832, 839, 845, 852, 861, 868, 874, 881, 1047, 1052, 1057, 1062, and 1067;(ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 6, 19, 27, 35, 45, 52, 56, 62, 69, 76, 83, 90, 109, 116, 123, 134, 142, 149, 156, 163, 169, 176, 183, 196, 209, 216, 223, 236, 273, 319, 328, 630, 776, 782, 789, 798, 804, 811, 818, 824, 833, 840, 846, 853, 862, 869, 875, 882, 1048, 1053, 1058, 1063, and 1068; and(iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 7, 13, 20, 28, 36, 40, 46, 53, 63, 70, 77, 84, 91, 97, 103, 110, 117, 124, 128, 135, 143, 150,157, 164, 170, 177, 184, 190, 197, 203, 210, 217, 224, 230, 237, 241, 244, 248, 253, 257, 259, 261, 263,265, 267, 269, 271, 274, 276, 278, 281, 297, 320, 322, 327, 330, 332, 631, 765, 767, 769, 774, 783, 790,793, 799, 805, 812, 819, 825, 834, 841, 847, 854, 857, 863, 870, 876, 883, 886, 1049, 1054, 1059, 1064, and 1069.

6. The antigen binding polypeptide of any one of claims 1-5, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ IDNOs: 4, 11, 17, 25, 33, 39, 43, 50, 60, 67, 74, 81, 88, 95, 101, 107, 114, 121, 127, 132, 140, 147, 154, 161,168, 174, 181, 188, 194, 201, 207, 214, 221, 228, 234, 240, 243, 247, 250, 251, 252, 255, 284, 286, 289,291, 293, 295, 299, 300, 302, 303, 305, 307, 308, 310, 312, 314, 315, 317, 323, 772, 780, 787, 796, 802,809, 816, 822, 831, 838, 844, 851, 860, 867, 873, 880, and 988;(b) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 8, 14, 21, 22, 29, 37, 47, 54, 57, 64, 71, 78, 85, 92, 98, 104, 111, 118, 125, 129, 136, 137, 144, 151, 158, 165, 171, 178, 185, 191, 198, 204, 211, 218, 225, 231, 238, 245, 254, 258, 260, 262, 264, 266, 268, 270, 272, 275, 277, 279, 280, 282, 298, 321, 331, 626, 775, 777, 784, 791, 800, 806, 813, 820, 826, 835, 842, 848, 855, 864, 871, 877, and 884;(c) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 4, 11, 17, 25, 33, 39, 43, 50, 60, 67, 74, 81, 88, 95, 101, 107, 114, 121, 127, 132, 140, 147, 154, 161,168, 174, 181, 188, 194, 201, 207, 214, 221, 228, 234, 240, 243, 247, 250, 251, 252, 255, 284, 286, 289,291, 293, 295, 299, 300, 302, 303, 305, 307, 308, 310, 312, 314, 315, 317, 323, 772, 780, 787, 796, 802,809, 816, 822, 831, 838, 844, 851, 860, 867, 873, 880, and 988; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 8, 14, 21, 22, 29, 37, 47, 54, 57, 64, 71, 78, 85, 92, 98, 104, 111, 118, 125, 129, 136, 137, 144, 151, 158, 165, 171, 178, 185, 191, 198, 204, 211, 218, 225, 231, 238, 245, 254, 258, 260, 262, 264, 266, 268, 270, 272, 275, 277, 279, 280, 282, 298, 321, 331, 626, 775, 777, 784, 791, 800, 806, 813, 820, 826, 835, 842, 848, 855, 864, 871, 877, and 884.

7. The antigen binding polypeptide of any one of claims 1 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332.

8. The antigen binding polypeptide of any one of claims 1 and 5-7, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29.

9. The antigen binding polypeptide of any one of claims 1 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059.

10. The antigen binding polypeptide of any one of claims 1, 5-6, and 9, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14.

11. The antigen binding polypeptide any one of claims 1 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059.

12. The antigen binding polypeptide of any one of claims 1, 5-6, and 11, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14.

13. The antigen binding polypeptide of any one of claims 1 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1 or 324, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 2 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 3;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 5, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 7.

14. The antigen binding polypeptide of any one of claims 1, 5-6, and 13 wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 4;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 8.

15. The antigen binding polypeptide of any one of claims 1 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 30, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 31 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 32, 38, or 326;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ IDNO: 34, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 35, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 36, 40, or 327.

16. The antigen binding polypeptide of any one of claims 1, 5-6, and 15 wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 33 or 39;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 37.

17. The antigen binding polypeptide of any one of claims 1 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631.

18. The antigen binding polypeptide of any one of claims 1, 5-6, and 17, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626.

19. The antigen binding polypeptide of any one of claims 1 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053,and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059.

20. The antigen binding polypeptide of any one of claims 1, 5-6, and 19, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14.

21. The antigen binding polypeptide of any one of claims 1 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

22. The antigen binding polypeptide of any one of claims 1, 5-6, and 21, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

23. The antigen binding polypeptide of any one of claims 1 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 152 or 1045, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1046 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 153 or 766;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630,and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 155 or 1047, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 156 or 1048, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 157, 767, or 1049.

24. The antigen binding polypeptide of any one of claims 1, 5-6, and 23, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 154;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 158.

25. The antigen binding polypeptide of any one of claims 1 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631.

26. The antigen binding polypeptide of any one of claims 1, 5-6, and 25, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626.

27. The antigen binding polypeptide of any one of claims 1 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 152 or 1045, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1046 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 153 or 766;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ IDNO: 155 or 1047, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 156 or 1048, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 157, 767, or 1049; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631.

28. The antigen binding polypeptide of any one of claims 1, 5-6, and 27, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 154;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 158; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626.

29. The antigen binding polypeptide of any one of claims 1 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 152 or 1045, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1046 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 153 or 766;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 155 or 1047, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 156 or 1048, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 157, 767, or 1049.

30. The antigen binding polypeptide of any one of claims 1, 5-6, and 29, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 154;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 158.

31. The antigen binding polypeptide of any one of claims 1 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ IDNO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054.

32. The antigen binding polypeptide of any one of claims 1, 5-6, and 31, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151.

33. The antigen binding polypeptide of any one of claims 1 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054.

34. The antigen binding polypeptide of any one of claims 1, 5-6, and 33, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151.

35. The antigen binding polypeptide of any one of claims 1 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 152 or 1045, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1046 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acidsequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 153 or 766;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 155 or 1047, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 156 or 1048, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 157, 767, or 1049.

36. The antigen binding polypeptide of any one of claims 1, 5-6, and 35, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 154;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 158.

37. The antigen binding polypeptide of any one of claims 1 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 172 or 1060, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1061 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence DAS, and a CDR3 having an amino acidsequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 173 or 792;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 175 or 1062, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 176 or 1063, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 177, 793, or 1064.

38. The antigen binding polypeptide of any one of claims 1, 5-6, and 37, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 174;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 178.

39. The antigen binding polypeptide of any one of claims 1 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 138 or 1065, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1061 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence DAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 139, 856, or 1066;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 152 or 1045, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1046 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acidsequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 153 or 766;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 141 or 1067, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 142 or 1068, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 143, 857, or 1069; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 155 or 1047, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 156 or 1048, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 157, 767, or 1049.

40. The antigen binding polypeptide of any one of claims 1, 5-6, and 39, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 140;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 154;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 144; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 158.

41. The antigen binding polypeptide of any one of claims 1 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acidsequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054.

42. The antigen binding polypeptide of any one of claims 1, 5-6, and 41, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151.

43. The antigen binding polypeptide of any one of claims 1 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 152 or 1045, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1046 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 153 or 766;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 152 or 1045, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1046 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acidsequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 153 or 766;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 155 or 1047, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 156 or 1048, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 157, 767, or 1049;(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 155 or 1047, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 156 or 1048, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 157, 767, or 1049.

44. The antigen binding polypeptide of any one of claims 1, 5-6, and 43, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 154;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 154;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 158; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 158.

45. The antigen binding polypeptide of any one of claims 1 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acidsequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059.

46. The antigen binding polypeptide of any one of claims 1, 5-6, and 45, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14.

47. The antigen binding polypeptide of any one of claims 3 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ IDNO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

48. The antigen binding polypeptide of any one of claims 3, 5-6, and 47, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

49. The antigen binding polypeptide of any one of claims 3 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

50. The antigen binding polypeptide of any one of claims 3, 5-6, and 49, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

51. The antigen binding polypeptide of any one of claims 3 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058,and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332.

52. The antigen binding polypeptide of any one of claims 3, 5-6, and 51, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical SEQ ID NO: 14; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29.

53. The antigen binding polypeptide of any one of claims 3 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1 or 324, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 2 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 3;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 5, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 7; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332.

54. The antigen binding polypeptide of any one of claims 3, 5-6, and 53, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 4;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 8; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29.

55. The antigen binding polypeptide of any one of claims 3 and 5-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 30, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 31 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 32, 38, or 326;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 34, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 35, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 36, 40, or 327; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ IDNO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

56. The antigen binding polypeptide of any one of claims 3, 5-6, and 55, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 33 or 39;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 37; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

57. The antigen binding polypeptide of any one of claims 4-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ IDNO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

58. The antigen binding polypeptide of any one of claims 4-6 and 57, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

59. The antigen binding polypeptide of any one of claims 4-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332.

60. The antigen binding polypeptide of any one of claims 4-6 and 59, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29.

61. The antigen binding polypeptide of any one of claims 4-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1 or 324, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 2 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 3;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 5, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 7; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332.

62. The antigen binding polypeptide of any one of claims 4-6 and 61, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 4;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 8; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29.

63. The antigen binding polypeptide of any one of claims 4-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

64. The antigen binding polypeptide of any one of claims 4-6 and 63, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

65. The antigen binding polypeptide of any one of claims 4-6, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 30, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 31 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 32, 38, or 326;(b) VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;(c) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 34, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 35, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 36, 40 or 327; and(d) VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

66. The antigen binding polypeptide of any one of claims 4-6, or 65 wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 33 or 39;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;(c) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 37; and(d) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

67. An antigen binding polypeptide having a structure, from amino -terminus to carboxy-terminus, represented by:VL 1 -L 1 -CL-L2-VH 1 -L3 -CHI ;VL 1 -L 1 -CH 1 -L2-VH 1 -L3 -CL;VH1-L1-CL-L2-VL1-L3-CH1; orVH 1 -L 1 -CH 1 -L2-VL 1 -L3-CL; wherein:VL1 is an immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein;VH1 is an immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein;CL is an immunoglobulin light chain constant region;CHI is an immunoglobulin heavy chain constant region 1; and L1-L3 are optional amino acid linkers.

68. The antigen binding polypeptide of claim 67, wherein:(a) VL1 comprises:(i) a complementarity determining region (CDR) 1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 1, 9, 15, 23, 30, 41, 48, 55, 58, 65, 72, 79, 86, 93, 99, 105, 112, 119, 130, 138, 145, 152, 159, 166, 172, 179, 186, 192, 199, 205, 212, 219, 226, 232, 324, 627, 770, 778, 785, 794, 801, 807, 814, 827, 836, 849, 858, 865, 878, 1045, 1050, 1055, 1060, and 1065;(ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 2, 31, 628, 1046, 1051, 1056, and 1061, or at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of amino acid sequences AAS, GAS, LGS, GTN, GTN, SAS, SDS, DNT, EVT, DAS, DVT, RNS, DVS, EDS, DDS, KDS, NNN, SYN, WAS, and DAT; and(iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 3, 10, 16, 24, 32, 38, 42, 49, 59, 66, 73, 80, 87, 94, 100, 106, 113, 120, 126, 131, 139, 146,153, 160, 167, 173, 180, 187, 193, 200, 206, 213, 220, 227, 233, 239, 242, 246, 249, 256, 283, 285, 287,288, 290, 292, 294, 296, 301, 304, 306, 309, 311, 313, 316, 325, 326, 329, 764, 766, 768, 771, 779, 786,792, 795, 808, 815, 821, 830, 837, 843, 850, 856, 859, 866, 872, 879, 885, and 1066; and(b) VH1 comprises(i) a CDR1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 5, 12, 18, 26, 34, 44, 51, 61, 68, 75, 82, 89, 96, 102, 108, 115, 122, 133, 141, 148, 155, 162, 175, 182, 189, 195, 202, 208, 215, 222, 229, 235, 318, 629, 773, 781, 788, 797, 803, 810, 817, 823, 832, 839, 845, 852, 861, 868, 874, 881, 1047, 1052, 1057, 1062, and 1067;(ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 6, 19, 27, 35, 45, 52, 56, 62, 69, 76, 83, 90, 109, 116, 123, 134, 142, 149, 156, 163, 169, 176, 183, 196, 209, 216, 223, 236, 273, 319, 328, 630, 776, 782, 789, 798, 804, 811, 818, 824, 833, 840, 846, 853, 862, 869, 875, 882, 1048, 1053, 1058, 1063, and 1068; and(iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 7, 13, 20, 28, 36, 40, 46, 53, 63, 70, 77, 84, 91, 97, 103, 110, 117, 124, 128, 135, 143, 150,157, 164, 170, 177, 184, 190, 197, 203, 210, 217, 224, 230, 237, 241, 244, 248, 253, 257, 259, 261, 263,265, 267, 269, 271, 274, 276, 278, 281, 297, 320, 322, 327, 330, 332, 631, 765, 767, 769, 774, 783, 790,793, 799, 805, 812, 819, 825, 834, 841, 847, 854, 857, 863, 870, 876, 883, 886, 1049, 1054, 1059, 1064, and 1069.

69. The antigen binding polypeptide of any one of claims 67 or 68, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 4, 11, 17, 25, 33, 39, 43, 50, 60, 67, 74, 81, 88, 95, 101, 107, 114, 121, 127, 132, 140, 147, 154, 161,168, 174, 181, 188, 194, 201, 207, 214, 221, 228, 234, 240, 243, 247, 250, 251, 252, 255, 284, 286, 289,291, 293, 295, 299, 300, 302, 303, 305, 307, 308, 310, 312, 314, 315, 317, 323, 772, 780, 787, 796, 802,809, 816, 822, 831, 838, 844, 851, 860, 867, 873, 880, and 988; and(b) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 8, 14, 21, 22, 29, 37, 47, 54, 57, 64, 71, 78, 85, 92, 98, 104, 111, 118, 125, 129, 136, 137, 144, 151,158, 165, 171, 178, 185, 191, 198, 204, 211, 218, 225, 231, 238, 245, 254, 258, 260, 262, 264, 266, 268, 270, 272, 275, 277, 279, 280, 282, 298, 321, 331, 626, 775, 777, 784, 791, 800, 806, 813, 820, 826, 835, 842, 848, 855, 864, 871, 877, and 884.

70. The antigen binding polypeptide any one of claims 67-69, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; and(b) VH1 comprises a CDR1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059.

71. The antigen binding polypeptide of any one of claims 67-70, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; and(b) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14.

72. An antigen binding polypeptide having a structure, from amino -terminus to carboxy-terminus, represented by:VL1-L1-VH1-L2-CL; orVH1-L1-VL1-L2-CL; wherein:VL1 is an immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein;VH1 is an immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein;CL is an immunoglobulin light chain constant region; andL1-L2 are optional amino acid linkers.

73. An antigen binding polypeptide having a structure, from amino -terminus to carboxy-terminus, represented by:VL1-L1-VH1-L2-CH1; orVH1-L1-VL1-L2-CH1; wherein:VL1 is an immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein;VH1 is an immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV-2 protein;CHI is an immunoglobulin heavy chain constant region 1; and L1-L2 are optional amino acid linkers.

74. The antigen binding polypeptide of claim 72 or 73, wherein:(a) VL1 comprises:(i) a complementarity determining region (CDR) 1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 1, 9, 15, 23, 30, 41, 48, 55, 58, 65, 72, 79, 86, 93, 99, 105, 112, 119, 130, 138, 145, 152, 159, 166, 172, 179, 186, 192, 199, 205, 212, 219, 226, 232, 324, 627, 770, 778, 785, 794, 801, 807, 814, 827, 836, 849, 858, 865, 878, 1045, 1050, 1055, 1060, and 1065;(ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 2, 31, 628, 1046, 1051, 1056, and 1061, or at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of amino acid sequences AAS, GAS, LGS, GTN, GTN, SAS, SDS, DNT, EVT, DAS, DVT, RNS, DVS, EDS, DDS, KDS, NNN, SYN, WAS, and DAT; and(iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 3, 10, 16, 24, 32, 38, 42, 49, 59, 66, 73, 80, 87, 94, 100, 106, 113, 120, 126, 131, 139, 146,153, 160, 167, 173, 180, 187, 193, 200, 206, 213, 220, 227, 233, 239, 242, 246, 249, 256, 283, 285, 287,288, 290, 292, 294, 296, 301, 304, 306, 309, 311, 313, 316, 325, 326, 329, 764, 766, 768, 771, 779, 786,792, 795, 808, 815, 821, 830, 837, 843, 850, 856, 859, 866, 872, 879, 885, and 1066; and(b) VH1 comprises:(i) a CDR1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 5, 12, 18, 26, 34, 44, 51, 61, 68, 75, 82, 89, 96, 102, 108, 115, 122, 133, 141, 148, 155, 162, 175, 182, 189, 195, 202, 208, 215, 222, 229, 235, 318, 629, 773, 781, 788, 797, 803, 810, 817, 823, 832, 839, 845, 852, 861, 868, 874, 881, 1047, 1052, 1057, 1062, and 1067;(ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 6, 19, 27, 35, 45, 52, 56, 62, 69, 76, 83, 90, 109, 116, 123, 134, 142, 149, 156, 163, 169, 176, 183, 196, 209, 216, 223, 236, 273, 319, 328, 630, 776, 782, 789, 798, 804, 811, 818, 824, 833, 840, 846, 853, 862, 869, 875, 882, 1048, 1053, 1058, 1063, and 1068; and(iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 7, 13, 20, 28, 36, 40, 46, 53, 63, 70, 77, 84, 91, 97, 103, 110, 117, 124, 128, 135, 143, 150, 157, 164, 170, 177, 184, 190, 197, 203, 210, 217, 224, 230, 237, 241, 244, 248, 253, 257, 259, 261, 263,265, 267, 269, 271, 274, 276, 278, 281, 297, 320, 322, 327, 330, 332, 631, 765, 767, 769, 774, 783, 790, 793, 799, 805, 812, 819, 825, 834, 841, 847, 854, 857, 863, 870, 876, 883, 886, 1049, 1054, 1059, 1064, and 1069.

75. The antigen binding polypeptide of any one of claims 72-74, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 4, 11, 17, 25, 33, 39, 43, 50, 60, 67, 74, 81, 88, 95, 101, 107, 114, 121, 127, 132, 140, 147, 154, 161, 168, 174, 181, 188, 194, 201, 207, 214, 221, 228, 234, 240, 243, 247, 250, 251, 252, 255, 284, 286, 289,291, 293, 295, 299, 300, 302, 303, 305, 307, 308, 310, 312, 314, 315, 317, 323, 772, 780, 787, 796, 802,809, 816, 822, 831, 838, 844, 851, 860, 867, 873, 880, and 988; and(b) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 8, 14, 21, 22, 29, 37, 47, 54, 57, 64, 71, 78, 85, 92, 98, 104, 111, 118, 125, 129, 136, 137, 144, 151, 158, 165, 171, 178, 185, 191, 198, 204, 211, 218, 225, 231, 238, 245, 254, 258, 260, 262, 264, 266, 268, 270, 272, 275, 277, 279, 280, 282, 298, 321, 331, 626, 775, 777, 784, 791, 800, 806, 813, 820, 826, 835, 842, 848, 855, 864, 871, 877, and 884.

76. The antigen binding polypeptide of any one of claims 72-75, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16; and(b) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

77. The antigen binding polypeptide of any one of claims 72-76, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17; and(b) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

78. The antigen binding polypeptide of any one of claims 72-75, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10; and(b) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059.

79. The antigen binding polypeptide of any one of claims 72-75 and 78, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11; and(b) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14.

80. The antigen binding polypeptide of any one of claims 72-75, wherein:(a) VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 72, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence DNT, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 73; and(b) VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 75, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 76, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 77.

81. The antigen binding polypeptide of any one of claims 72-75 and 80 wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 74; and(b) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 78.

82. An antigen binding polypeptide having a structure, from amino -terminus to carboxy-terminus, represented by:VL1-L1-VL2-L2-CH1; orVL2-L1-VL1-L2-CH1; whereinVL1 is a first immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein;VL2 is a second immunoglobulin light chain variable region that specifically binds to a SARS- CoV-2 protein;CHI is an immunoglobulin heavy chain constant region 1; and L1-L2 are optional amino acid linkers.

83. The antigen binding polypeptide of claim 82, wherein:(a) VL1 comprises:(i) a complementarity determining region (CDR) 1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 1, 9, 15, 23, 30, 41, 48, 55, 58, 65, 72, 79, 86, 93, 99, 105, 112, 119, 130, 138, 145, 152, 159, 166, 172, 179, 186, 192, 199, 205, 212, 219, 226, 232, 324, 627, 770, 778, 785, 794, 801, 807, 814, 827, 836, 849, 858, 865, 878, 1045, 1050, 1055, 1060, and 1065;(ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 2, 31, 628, 1046, 1051, 1056, and 1061, or at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of amino acid sequences AAS, GAS, LGS, GTN, GTN, SAS, SDS, DNT, EVT, DAS, DVT, RNS, DVS, EDS, DDS, KDS, NNN, SYN, WAS, and DAT; and(iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 3, 10, 16, 24, 32, 38, 42, 49, 59, 66, 73, 80, 87, 94, 100, 106, 113, 120, 126, 131, 139, 146,153, 160, 167, 173, 180, 187, 193, 200, 206, 213, 220, 227, 233, 239, 242, 246, 249, 256, 283, 285, 287,288, 290, 292, 294, 296, 301, 304, 306, 309, 311, 313, 316, 325, 326, 329, 764, 766, 768, 771, 779, 786,792, 795, 808, 815, 821, 830, 837, 843, 850, 856, 859, 866, 872, 879, 885, and 1066; and(b) VL2 comprises:(i) a complementarity determining region (CDR) 1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 1, 9, 15, 23, 30, 41, 48, 55, 58, 65, 72, 79, 86, 93, 99, 105, 112, 119, 130, 138, 145, 152, 159, 166, 172, 179, 186, 192, 199, 205, 212, 219, 226, 232, 324, 627, 770, 778, 785, 794, 801, 807, 814, 827, 836, 849, 858, 865, 878, 1045, 1050, 1055, 1060, and 1065;(ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one ofSEQ ID NOs: 2, 31, 628, 1046, 1051, 1056, and 1061, or at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of amino acid sequences AAS, GAS, LGS, GTN, GTN, SAS, SDS, DNT, EVT, DAS, DVT, RNS, DVS, EDS, DDS, KDS, NNN, SYN, WAS, and DAT; and(iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 3, 10, 16, 24, 32, 38, 42, 49, 59, 66, 73, 80, 87, 94, 100, 106, 113, 120, 126, 131, 139, 146,153, 160, 167, 173, 180, 187, 193, 200, 206, 213, 220, 227, 233, 239, 242, 246, 249, 256, 283, 285, 287,288, 290, 292, 294, 296, 301, 304, 306, 309, 311, 313, 316, 325, 326, 329, 764, 766, 768, 771, 779, 786,792, 795, 808, 815, 821, 830, 837, 843, 850, 856, 859, 866, 872, 879, 885, and 1066.

84. The antigen binding polypeptide of claim 82 or 83, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 4, 11, 17, 25, 33, 39, 43, 50, 60, 67, 74, 81, 88, 95, 101, 107, 114, 121, 127, 132, 140, 147, 154, 161,168, 174, 181, 188, 194, 201, 207, 214, 221, 228, 234, 240, 243, 247, 250, 251, 252, 255, 284, 286, 289,291, 293, 295, 299, 300, 302, 303, 305, 307, 308, 310, 312, 314, 315, 317, 323, 772, 780, 787, 796, 802,809, 816, 822, 831, 838, 844, 851, 860, 867, 873, 880, and 988; and(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 4, 11, 17, 25, 33, 39, 43, 50, 60, 67, 74, 81, 88, 95, 101, 107, 114, 121, 127, 132, 140, 147, 154, 161,168, 174, 181, 188, 194, 201, 207, 214, 221, 228, 234, 240, 243, 247, 250, 251, 252, 255, 284, 286, 289,291, 293, 295, 299, 300, 302, 303, 305, 307, 308, 310, 312, 314, 315, 317, 323, 772, 780, 787, 796, 802,809, 816, 822, 831, 838, 844, 851, 860, 867, 873, 880, and 988.

85. An antigen binding polypeptide having a structure, from amino -terminus to carboxy -terminus, represented by:VH1-L1-VH2-L2-CL; orVH2-L1-VH1-L2-CL; whereinVH1 is a first immunoglobulin heavy chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein;VH2 is a second immunoglobulin heavy chain variable region that specifically binds to a SARS- CoV-2 protein;CL is an immunoglobulin light chain constant region; andL1-L2 are optional amino acid linkers.

86. The antigen binding polypeptide of claim 85, wherein:(a) VH1 comprises:(i) a CDR1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 5, 12, 18, 26, 34, 44, 51, 61, 68, 75, 82, 89, 96, 102, 108, 115, 122, 133, 141, 148, 155, 162, 175, 182, 189, 195, 202, 208, 215, 222, 229, 235, 318, 629, 773, 781, 788, 797, 803, 810, 817, 823, 832, 839, 845, 852, 861, 868, 874, 881, 1047, 1052, 1057, 1062, and 1067;(ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 6, 19, 27, 35, 45, 52, 56, 62, 69, 76, 83, 90, 109, 116, 123, 134, 142, 149, 156, 163, 169, 176, 183, 196, 209, 216, 223, 236, 273, 319, 328, 630, 776, 782, 789, 798, 804, 811, 818, 824, 833, 840, 846, 853, 862, 869, 875, 882, 1048, 1053, 1058, 1063, and 1068; and(iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 7, 13, 20, 28, 36, 40, 46, 53, 63, 70, 77, 84, 91, 97, 103, 110, 117, 124, 128, 135, 143, 150,157, 164, 170, 177, 184, 190, 197, 203, 210, 217, 224, 230, 237, 241, 244, 248, 253, 257, 259, 261, 263,265, 267, 269, 271, 274, 276, 278, 281, 297, 320, 322, 327, 330, 332, 631, 765, 767, 769, 774, 783, 790,793, 799, 805, 812, 819, 825, 834, 841, 847, 854, 857, 863, 870, 876, 883, 886, 1049, 1054, 1059, 1064, and 1069; and(b) VH2 comprises:(i) a CDR1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 5, 12, 18, 26, 34, 44, 51, 61, 68, 75, 82, 89, 96, 102, 108, 115, 122, 133, 141, 148, 155, 162, 175, 182, 189, 195, 202, 208, 215, 222, 229, 235, 318, 629, 773, 781, 788, 797, 803, 810, 817, 823, 832, 839, 845, 852, 861, 868, 874, 881, 1047, 1052, 1057, 1062, and 1067;(ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 6, 19, 27, 35, 45, 52, 56, 62, 69, 76, 83, 90, 109, 116, 123, 134, 142, 149, 156, 163, 169, 176, 183, 196, 209, 216, 223, 236, 273, 319, 328, 630, 776, 782, 789, 798, 804, 811, 818, 824, 833, 840, 846, 853, 862, 869, 875, 882, 1048, 1053, 1058, 1063, and 1068; and(iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 7, 13, 20, 28, 36, 40, 46, 53, 63, 70, 77, 84, 91, 97, 103, 110, 117, 124, 128, 135, 143, 150,157, 164, 170, 177, 184, 190, 197, 203, 210, 217, 224, 230, 237, 241, 244, 248, 253, 257, 259, 261, 263,265, 267, 269, 271, 274, 276, 278, 281, 297, 320, 322, 327, 330, 332, 631, 765, 767, 769, 774, 783, 790,793, 799, 805, 812, 819, 825, 834, 841, 847, 854, 857, 863, 870, 876, 883, 886, 1049, 1054, 1059, 1064, and 1069.

87. The antigen binding polypeptide of claim 85 or 86, wherein:(a) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ IDNOs: 8, 14, 21, 22, 29, 37, 47, 54, 57, 64, 71, 78, 85, 92, 98, 104, 111, 118, 125, 129, 136, 137, 144, 151, 158, 165, 171, 178, 185, 191, 198, 204, 211, 218, 225, 231, 238, 245, 254, 258, 260, 262, 264, 266, 268, 270, 272, 275, 277, 279, 280, 282, 298, 321, 331, 626, 775, 777, 784, 791, 800, 806, 813, 820, 826, 835, 842, 848, 855, 864, 871, 877, and 884; and(b) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 8, 14, 21, 22, 29, 37, 47, 54, 57, 64, 71, 78, 85, 92, 98, 104, 111, 118, 125, 129, 136, 137, 144, 151, 158, 165, 171, 178, 185, 191, 198, 204, 211, 218, 225, 231, 238, 245, 254, 258, 260, 262, 264, 266, 268, 270, 272, 275, 277, 279, 280, 282, 298, 321, 331, 626, 775, 777, 784, 791, 800, 806, 813, 820, 826, 835, 842, 848, 855, 864, 871, 877, and 884.

88. An antigen binding polypeptide having a structure, from amino -terminus to carboxy-terminus, represented by:VL 1 -L 1 -VL2-L2-VL3 -L3-CH 1 ;VL 1 -L 1 -VL3 -L2-VL2-L3-CH 1 ;VL2-L 1 -VL 1 -L2-VL3 -L3-CH 1 ;VL2-L 1 -VL3 -L2-VL 1 -L3-CH 1 ;VL3-L1-VL1-L2-VL2-L3-CH1; orVL3 -L 1 -VL2-L2-VL 1 -L3-CH 1 ; whereinVL1 is a first immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein;VL2 is a second immunoglobulin light chain variable region that specifically binds to a SARS- CoV-2 protein;VL3 is a third immunoglobulin light chain variable region that specifically binds to a SARS-CoV- 2 protein;CHI is an immunoglobulin heavy chain constant region 1; andL1-L3 are optional amino acid linkers.

89. The antigen binding polypeptide of claim 88, wherein:(a) VL1 comprises:(i) a complementarity determining region (CDR) 1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 1, 9, 15, 23, 30, 41, 48, 55, 58, 65, 72, 79, 86, 93, 99, 105, 112, 119, 130, 138, 145, 152, 159, 166, 172, 179, 186, 192, 199, 205, 212, 219, 226, 232, 324, 627, 770, 778, 785, 794, 801, 807, 814, 827, 836, 849, 858, 865, 878, 1045, 1050, 1055, 1060, and 1065;(ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 2, 31, 628, 1046, 1051, 1056, and 1061, or at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of amino acidsequences AAS, GAS, LGS, GTN, GTN, SAS, SDS, DNT, EVT, DAS, DVT, RNS, DVS, EDS, DDS, KDS, NNN, SYN, WAS, and DAT; and(iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 3, 10, 16, 24, 32, 38, 42, 49, 59, 66, 73, 80, 87, 94, 100, 106, 113, 120, 126, 131, 139, 146,153, 160, 167, 173, 180, 187, 193, 200, 206, 213, 220, 227, 233, 239, 242, 246, 249, 256, 283, 285, 287,288, 290, 292, 294, 296, 301, 304, 306, 309, 311, 313, 316, 325, 326, 329, 764, 766, 768, 771, 779, 786,792, 795, 808, 815, 821, 830, 837, 843, 850, 856, 859, 866, 872, 879, 885, and 1066;(b) VL2 comprises:(i) a complementarity determining region (CDR) 1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 1, 9, 15, 23, 30, 41, 48, 55, 58, 65, 72, 79, 86, 93, 99, 105, 112, 119, 130, 138, 145, 152, 159, 166, 172, 179, 186, 192, 199, 205, 212, 219, 226, 232, 324, 627, 770, 778, 785, 794, 801, 807, 814, 827, 836, 849, 858, 865, 878, 1045, 1050, 1055, 1060, and 1065;(ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 2, 31, 628, 1046, 1051, 1056, and 1061, or at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of amino acid sequences AAS, GAS, LGS, GTN, GTN, SAS, SDS, DNT, EVT, DAS, DVT, RNS, DVS, EDS, DDS, KDS, NNN, SYN, WAS, and DAT; and(iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 3, 10, 16, 24, 32, 38, 42, 49, 59, 66, 73, 80, 87, 94, 100, 106, 113, 120, 126, 131, 139, 146,153, 160, 167, 173, 180, 187, 193, 200, 206, 213, 220, 227, 233, 239, 242, 246, 249, 256, 283, 285, 287,288, 290, 292, 294, 296, 301, 304, 306, 309, 311, 313, 316, 325, 326, 329, 764, 766, 768, 771, 779, 786,792, 795, 808, 815, 821, 830, 837, 843, 850, 856, 859, 866, 872, 879, 885, and 1066; and(c) VL3 comprises:(i) a complementarity determining region (CDR) 1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 1, 9, 15, 23, 30, 41, 48, 55, 58, 65, 72, 79, 86, 93, 99, 105, 112, 119, 130, 138, 145, 152, 159, 166, 172, 179, 186, 192, 199, 205, 212, 219, 226, 232, 324, 627, 770, 778, 785, 794, 801, 807, 814, 827, 836, 849, 858, 865, 878, 1045, 1050, 1055, 1060, and 1065;(ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 2, 31, 628, 1046, 1051, 1056, and 1061, or at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of amino acid sequences AAS, GAS, LGS, GTN, GTN, SAS, SDS, DNT, EVT, DAS, DVT, RNS, DVS, EDS, DDS, KDS, NNN, SYN, WAS, and DAT; and(iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 3, 10, 16, 24, 32, 38, 42, 49, 59, 66, 73, 80, 87, 94, 100, 106, 113, 120, 126, 131, 139, 146, 153, 160, 167, 173, 180, 187, 193, 200, 206, 213, 220, 227, 233, 239, 242, 246, 249, 256, 283, 285, 287,288, 290, 292, 294, 296, 301, 304, 306, 309, 311, 313, 316, 325, 326, 329, 764, 766, 768, 771, 779, 786,792, 795, 808, 815, 821, 830, 837, 843, 850, 856, 859, 866, 872, 879, 885, and 1066.

90. The antigen binding polypeptide of claim 88 or 89, wherein:(a) VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 4, 11, 17, 25, 33, 39, 43, 50, 60, 67, 74, 81, 88, 95, 101, 107, 114, 121, 127, 132, 140, 147, 154, 161,168, 174, 181, 188, 194, 201, 207, 214, 221, 228, 234, 240, 243, 247, 250, 251, 252, 255, 284, 286, 289,291, 293, 295, 299, 300, 302, 303, 305, 307, 308, 310, 312, 314, 315, 317, 323, 772, 780, 787, 796, 802,809, 816, 822, 831, 838, 844, 851, 860, 867, 873, 880, and 988;(b) VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 4, 11, 17, 25, 33, 39, 43, 50, 60, 67, 74, 81, 88, 95, 101, 107, 114, 121, 127, 132, 140, 147, 154, 161,168, 174, 181, 188, 194, 201, 207, 214, 221, 228, 234, 240, 243, 247, 250, 251, 252, 255, 284, 286, 289,291, 293, 295, 299, 300, 302, 303, 305, 307, 308, 310, 312, 314, 315, 317, 323, 772, 780, 787, 796, 802,809, 816, 822, 831, 838, 844, 851, 860, 867, 873, 880, and 988; and(c) VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 4, 11, 17, 25, 33, 39, 43, 50, 60, 67, 74, 81, 88, 95, 101, 107, 114, 121, 127, 132, 140, 147, 154, 161,168, 174, 181, 188, 194, 201, 207, 214, 221, 228, 234, 240, 243, 247, 250, 251, 252, 255, 284, 286, 289,291, 293, 295, 299, 300, 302, 303, 305, 307, 308, 310, 312, 314, 315, 317, 323, 772, 780, 787, 796, 802,809, 816, 822, 831, 838, 844, 851, 860, 867, 873, 880, and 988.

91. An antigen binding polypeptide having a structure, from amino -terminus to carboxy-terminus, represented by:VH 1 -L 1 -VH2-L2-VH3 -L3 -CL;VH 1 -L 1 -VH3 -L2-VH2-L3 -CL;VH2-L 1 -VH 1 -L2-VH3 -L3 -CL;VH2-L 1 -VH3 -L2-VH 1 -L3 -CL;VH3-L1-VH1-L2-VH2-L3-CL; orVH3 -L 1 -VH2-L2-VH 1 -L3 -CL; whereinVH1 is a first immunoglobulin heavy chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein;VH2 is a second immunoglobulin heavy chain variable region that specifically binds to a SARS- CoV-2 protein;VH3 is a third immunoglobulin heavy chain variable region that specifically binds to a SARS- CoV-2 protein;CL is an immunoglobulin light chain constant region; and L1-L3 are optional amino acid linkers.

92. The antigen binding polypeptide of claim 91 , wherein:(a) VH1 comprises:(i) a CDR1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 5, 12, 18, 26, 34, 44, 51, 61, 68, 75, 82, 89, 96, 102, 108, 115, 122, 133, 141, 148, 155, 162, 175, 182, 189, 195, 202, 208, 215, 222, 229, 235, 318, 629, 773, 781, 788, 797, 803, 810, 817, 823, 832, 839, 845, 852, 861, 868, 874, 881, 1047, 1052, 1057, 1062, and 1067;(ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 6, 19, 27, 35, 45, 52, 56, 62, 69, 76, 83, 90, 109, 116, 123, 134, 142, 149, 156, 163, 169, 176, 183, 196, 209, 216, 223, 236, 273, 319, 328, 630, 776, 782, 789, 798, 804, 811, 818, 824, 833, 840, 846, 853, 862, 869, 875, 882, 1048, 1053, 1058, 1063, and 1068; and(iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 7, 13, 20, 28, 36, 40, 46, 53, 63, 70, 77, 84, 91, 97, 103, 110, 117, 124, 128, 135, 143, 150,157, 164, 170, 177, 184, 190, 197, 203, 210, 217, 224, 230, 237, 241, 244, 248, 253, 257, 259, 261, 263,265, 267, 269, 271, 274, 276, 278, 281, 297, 320, 322, 327, 330, 332, 631, 765, 767, 769, 774, 783, 790,793, 799, 805, 812, 819, 825, 834, 841, 847, 854, 857, 863, 870, 876, 883, 886, 1049, 1054, 1059, 1064, and 1069;(b) VH2 comprises:(i) a CDR1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 5, 12, 18, 26, 34, 44, 51, 61, 68, 75, 82, 89, 96, 102, 108, 115, 122, 133, 141, 148, 155, 162, 175, 182, 189, 195, 202, 208, 215, 222, 229, 235, 318, 629, 773, 781, 788, 797, 803, 810, 817, 823, 832, 839, 845, 852, 861, 868, 874, 881, 1047, 1052, 1057, 1062, and 1067;(ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 6, 19, 27, 35, 45, 52, 56, 62, 69, 76, 83, 90, 109, 116, 123, 134, 142, 149, 156, 163, 169, 176, 183, 196, 209, 216, 223, 236, 273, 319, 328, 630, 776, 782, 789, 798, 804, 811, 818, 824, 833, 840, 846, 853, 862, 869, 875, 882, 1048, 1053, 1058, 1063, and 1068; and(iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 7, 13, 20, 28, 36, 40, 46, 53, 63, 70, 77, 84, 91, 97, 103, 110, 117, 124, 128, 135, 143, 150, 157, 164, 170, 177, 184, 190, 197, 203, 210, 217, 224, 230, 237, 241, 244, 248, 253, 257, 259, 261, 263,265, 267, 269, 271, 274, 276, 278, 281, 297, 320, 322, 327, 330, 332, 631, 765, 767, 769, 774, 783, 790, 793, 799, 805, 812, 819, 825, 834, 841, 847, 854, 857, 863, 870, 876, 883, 886, 1049, 1054, 1059, 1064, and 1069; and(c) VH3 comprises:(i) a CDR1 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 5, 12, 18, 26, 34, 44, 51, 61, 68, 75, 82, 89, 96, 102, 108, 115, 122, 133, 141, 148, 155, 162, 175, 182, 189, 195, 202, 208, 215, 222, 229, 235, 318, 629, 773, 781, 788, 797, 803, 810, 817, 823, 832, 839, 845, 852, 861, 868, 874, 881, 1047, 1052, 1057, 1062, and 1067;(ii) a CDR2 having an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 6, 19, 27, 35, 45, 52, 56, 62, 69, 76, 83, 90, 109, 116, 123, 134, 142, 149, 156, 163, 169, 176, 183, 196, 209, 216, 223, 236, 273, 319, 328, 630, 776, 782, 789, 798, 804, 811, 818, 824, 833, 840, 846, 853, 862, 869, 875, 882, 1048, 1053, 1058, 1063, and 1068; and(iii) a CDR3 having an amino acid sequence that is at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 7, 13, 20, 28, 36, 40, 46, 53, 63, 70, 77, 84, 91, 97, 103, 110, 117, 124, 128, 135, 143, 150,157, 164, 170, 177, 184, 190, 197, 203, 210, 217, 224, 230, 237, 241, 244, 248, 253, 257, 259, 261, 263,265, 267, 269, 271, 274, 276, 278, 281, 297, 320, 322, 327, 330, 332, 631, 765, 767, 769, 774, 783, 790,793, 799, 805, 812, 819, 825, 834, 841, 847, 854, 857, 863, 870, 876, 883, 886, 1049, 1054, 1059, 1064, and 1069.

93. The antigen binding polypeptide of claim 91 or 92, wherein:(a) VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 8, 14, 21, 22, 29, 37, 47, 54, 57, 64, 71, 78, 85, 92, 98, 104, 111, 118, 125, 129, 136, 137, 144, 151,158, 165, 171, 178, 185, 191, 198, 204, 211, 218, 225, 231, 238, 245, 254, 258, 260, 262, 264, 266, 268, 270, 272, 275, 277, 279, 280, 282, 298, 321, 331, 626, 775, 777, 784, 791, 800, 806, 813, 820, 826, 835, 842, 848, 855, 864, 871, 877, and 884;(b) VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 8, 14, 21, 22, 29, 37, 47, 54, 57, 64, 71, 78, 85, 92, 98, 104, 111, 118, 125, 129, 136, 137, 144, 151, 158, 165, 171, 178, 185, 191, 198, 204, 211, 218, 225, 231, 238, 245, 254, 258, 260, 262, 264, 266, 268, 270, 272, 275, 277, 279, 280, 282, 298, 321, 331, 626, 775, 777, 784, 791, 800, 806, 813, 820, 826, 835, 842, 848, 855, 864, 871, 877, and 884; and(c) VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 8, 14, 21, 22, 29, 37, 47, 54, 57, 64, 71, 78, 85, 92, 98, 104, 111, 118, 125, 129, 136, 137, 144, 151, 158, 165, 171, 178, 185, 191, 198, 204, 211, 218, 225, 231, 238, 245, 254, 258, 260, 262, 264, 266, 268,270, 272, 275, 277, 279, 280, 282, 298, 321, 331, 626, 775, 777, 784, 791, 800, 806, 813, 820, 826, 835, 842, 848, 855, 864, 871, 877, and 884.

94. The antigen binding polypeptide of any one of claims 1-93, wherein the antigen binding polypeptide further comprises an Fc region at the carboxy -terminus.

95. The antigen binding polypeptide of claim 94, wherein the Fc region comprises an immunoglobulin heavy chain constant region 2 (CH2) and / or an immunoglobulin heavy chain constant region 3 (CH3).

96. The antigen binding polypeptide of claim 94 or 95, wherein the Fc region further comprises an immunoglobulin hinge.

97. The antigen binding polypeptide of any one of claims 94-96, wherein the Fc region comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to any one of SEQ ID NOs: 376-380.

98. The antigen binding polypeptide of any one of claims 94-97, wherein the Fc region comprises one or more half-life extension amino acid substitutions.

99. The antigen binding polypeptide of claim 98, wherein the one or more half-life extension amino acid substitutions comprise one or more of amino acid substitutions M428L, N434A, N434S, L234F, L235E, P33 IS, M252Y, S254T, or T256E, or equivalent thereof, based on the EU numbering scheme.

100. The antigen binding polypeptide of claim 98 or 99, wherein the one or more half-life extension amino acid substitutions comprise amino acid substitutions:(i) L234A and L235A (LA);(ii) M428L and N434S (LS);(iii) L234F and L235E;(iv) L234F, L235E, and P33 IS (TM); and / or(v) M252Y, S254T, and T256E (YTE); or equivalent thereof, based on the EU numbering scheme.

101. An antigen binding polypeptide complex comprising a first polypeptide and a second polypeptide, wherein the first polypeptide has a structure, from amino -terminus to carboxy-terminus, represented by:VL 1 -L 1 -CL-L2-VL2-L3 -VH2-L4-VH 1 -L5-CH 1 ;VL 1 -L 1 -CL-L2-VH2-L3 -VL2-L4-VH 1 -L5-CH 1 ;VL 1 -L 1 -CH 1 -L2-VL2-L3-VH2-L4-VH 1-L5-CL;VL 1 -L 1 -CH 1 -L2-VH2-L3 -VL2-L4-VH 1 -L5-CL;VH 1 -L 1 -CL-L2-VL2-L3 -VH2-L4-VL 1 -L5-CH 1 ;VH 1 -L 1 -CL-L2-VH2-L3-VL2-L4-VL 1 -L5-CH 1 ;VH 1 -L 1-CH 1 -L2-VL2-L3-VH2-L4-VL 1 -L5-CL;VH 1 -L 1 -CH 1 -L2-VH2-L3 -VL2-L4-VL 1-L5-CL;VL2-L 1 -CL-L2-VL 1 -L3-VH 1 -L4-VH2-L5-CH 1 ;VL2-L 1 -CL-L2-VH 1 -L3 -VL 1 -L4-VH2-L5-CH 1 ;VL2-L 1 -CH 1 -L2-VL 1 -L3 -VH 1 -L4-VH2-L5-CL;VL2-L 1 -CH 1 -L2-VH 1 -L3 -VL 1 -L4-VH2-L5-CL;VH2-L1-CL-L2-VL1-L3-VH1-L4-VL2-L5-CH1;VH2-L 1 -CL-L2-VH 1-L3 -VL 1 -L4-VL2-L5-CH 1 ;VH2-L1-CH1-L2-VL1-L3-VH1-L4-VL2-L5-CL; orVH2-L 1 -CH 1 -L2-VH 1 -L3 -VL 1 -L4-VL2-L5-CL; wherein the second polypeptide has a structure, from amino-terminus to carboxy -terminus, represented by:VL3-L6-CL-L7-VL4-L8-VH4-L9-VH3-L10-CH1;VL3-L6-CL-L7-VH4-L8-VL4-L9-VH3-L10-CH1;VL3-L6-CH1-L7-VL4-L8-VH4-L9-VH3-L10-CL;VL3-L6-CH1-L7-VH4-L8-VL4-L9-VH3-L10-CL;VH3-L6-CL-L7-VL4-L8-VH4-L9-VL3-L10-CH1;VH3-L6-CL-L7-VH4-L8-VL4-L9-VL3-L10-CH1;VH3-L6-CH1-L7-VL4-L8-VH4-L9-VL3-L10-CL;VH3-L6-CH1-L7-VH4-L8-VL4-L9-VL3-L10-CL;VL4-L6-CL-L7-VL3-L8-VH3-L9-VH4-L10-CH1;VL4-L6-CL-L7-VH3-L8-VL3-L9-VH4-L10-CH1;VL4-L6-CH1-L7-VL3-L8-VH3-L9-VH4-L10-CL;VL4-L6-CH1-L7-VH3-L8-VL3-L9-VH4-L10-CL;VH4-L6-CL-L7-VL3-L8-VH3-L9-VL4-L10-CH1;VH4-L6-CL-L7-VH3-L8-VL3-L9-VL4-L10-CH1;VH4-L6-CH1-L7-VL3-L8-VH3-L9-VL4-L10-CL; orVH4-L6-CH1-L7-VH3-L8-VL3-L9-VL4-L10-CL; and wherein:VL1 is a first immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein;VL2 is a second immunoglobulin light chain variable region that specifically binds to a SARS- CoV-2 protein;VL3 is a third immunoglobulin light chain variable region that specifically binds to a SARS-CoV- 2 protein;VL4 is a fourth immunoglobulin light chain variable region that specifically binds to a SARS- CoV-2 protein;VH1 is a first immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV- 2 protein;VH2 is a second immunoglobulin heavy chain variable region that specifically binds to a SARS- CoV-2 protein;VH3 is a third immunoglobulin heavy chain variable region that specifically binds to a SARS- CoV-2 protein;VH4 is a fourth immunoglobulin heavy chain variable region that specifically binds to a SARS- CoV-2 protein;CL is an immunoglobulin light chain constant region;CHI is an immunoglobulin heavy chain constant region 1; and L1-L10 are optional amino acid linkers.

102. An antigen binding polypeptide complex comprising a first polypeptide and a second polypeptide, wherein the first polypeptide has a structure, from amino -terminus to carboxy -terminus, represented by:VL 1 -CL-L 1 -VL2-L2- VH2-L3 - VH 1 -CH 1 ;VL 1 -CL-L 1 -VH2-L2-VL2-L3 - VH 1 -CH 1 ;VL 1 -CH 1 -L 1 -VL2-L2-VH2-L3 -VH 1-CL;VL 1 -CH 1 -L 1 - VH2-L2- VL2-L3 -VH 1 -CL ;VH 1 -CL-L 1 -VL2-L2-VH2-L3 -VL 1 -CH 1 ;VH 1 -CL-L 1 -VH2-L2-VL2-L3 -VL 1 -CH 1 ;VH 1 -CH 1 -L 1 -VL2-L2-VH2-L3 -VL 1 -CL;VH 1 -CH 1 -L 1 -VH2-L2-VL2-L3 -VL 1 -CL;VL2-CL-L 1 -VL 1 -L2-VH 1 -L3 -VH2-CH 1 ;VL2-CL-L 1 -VH 1-L2-VL 1 -L3 -VH2-CH 1 ;VL2-CH 1 -L 1 -VL 1 -L2-VH 1-L3 -VH2-CL;VL2-CH 1 -L 1 - VH 1 -L2- VL 1 -L3 -VH2-CL ;VH2-CL-L 1 -VL 1 -L2-VH 1 -L3 -VL2-CH 1 ;VH2-CL-L 1 -VH 1 -L2-VL 1 -L3 -VL2-CH 1 ;VH2-CH1-L1-VL1-L2-VH1-L3-VL2-CL; orVH2-CH 1 -L 1 -VH 1 -L2-VL 1 -L3 -VL2-CL; wherein the second polypeptide has a structure, from amino-terminus to carboxy-terminus, represented by:VL3-CL-L4-VL4-L5-VH4-L6-VH3-CH1;VL3-CL-L4-VH4-L5-VL4-L6-VH3-CH1;VL3-CH1-L4-VL4-L5-VH4-L6-VH3-CL;VL3-CH1-L4-VH4-L5-VL4-L6-VH3-CL;VH3-CL-L4-VL4-L5-VH4-L6-VL3-CH1;VH3 -CL-L4-VH4-L5-VL4-L6-VL3 -CH 1 ;VH3 -CH 1 -L4-VL4-L5-VH4-L6-VL3 -CL;VH3 -CH 1 -L4-VH4-L5-VL4-L6-VL3 -CL;VL4-CL-L4-VL3 -L5-VH3 -L6-VH4-CH 1 ;VL4-CL-L4-VH3-L5-VL3-L6-VH4-CH1;VL4-CH1-L4-VL3-L5-VH3-L6-VH4-CL;VL4-CH1-L4-VH3-L5-VL3-L6-VH4-CL;VH4-CL-L4-VL3-L5-VH3-L6-VL4-CH1;VH4-CL-L4-VH3-L5-VL3-L6-VL4-CH1;VH4-CH1-L4-VL3-L5-VH3-L6-VL4-CL; or VH4-CH1-L4-VH3-L5-VL3-L6-VL4-CL; and wherein:VL1 is a first immunoglobulin light chain variable region that specifically binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein;VL2 is a second immunoglobulin light chain variable region that specifically binds to a SARS- CoV-2 protein;VL3 is a third immunoglobulin light chain variable region that specifically binds to a SARS-CoV- 2 protein;VL4 is a fourth immunoglobulin light chain variable region that specifically binds to a SARS- CoV-2 protein;VH1 is a first immunoglobulin heavy chain variable region that specifically binds to a SARS-CoV- 2 protein;VH2 is a second immunoglobulin heavy chain variable region that specifically binds to a SARS- CoV-2 protein;VH3 is a third immunoglobulin heavy chain variable region that specifically binds to a SARS- CoV-2 protein;VH4 is a fourth immunoglobulin heavy chain variable region that specifically binds to a SARS- CoV-2 protein;CL is an immunoglobulin light chain constant region;CHI is an immunoglobulin heavy chain constant region 1; andL1-L6 are amino acid linkers.

103. The antigen binding polypeptide complex of claim 101 or 102, wherein:VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059;VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20;VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; andVH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

104. The antigen binding polypeptide complex of any one of claims 101-103, wherein:VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14;VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22;VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; andVH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

105. The antigen binding polypeptide complex of claim 101 or 102, wherein:VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325;VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332;VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059;VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; andVH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

106. The antigen binding polypeptide complex of claim 101, 102 or 105, wherein:VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25;VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29;VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14;VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; andVH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

107. The antigen binding polypeptide complex claim 101 or 102, wherein:VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 23, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GTN, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 24 or 325;VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1 or 324, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 2 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 3;VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 30, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 31 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 32, 38, or 326;VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 26, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 27, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 28 or 332;VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 5, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 7;VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; andVH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 34, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 35, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 36, 40, or 327.

108. The antigen binding polypeptide complex of claim 101, 102, or 107, wherein:VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 25;VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 4;VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 33 or 39;VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 29;VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 8;VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; andVH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 37.

109. The antigen binding polypeptide complex of claim 101 or 102, wherein:VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059;VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631;VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; andVH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

110. The antigen binding polypeptide complex of claim 101, 102, or 109, wherein:VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14;VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626;VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; andVH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

111. The antigen binding polypeptide complex of claim 101 or 102, wherein:VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to CDR1 SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to CDR1 SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 152 or 1045, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1046 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 153 or 766;VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059;VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631;VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 155 or 1047, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 156 or 1048, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 157, 767, or 1049.

112. The antigen binding polypeptide complex of claim 101, 102, or 111, wherein:VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 154;VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14;VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626;VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14; and VH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 158.

113. The antigen binding polypeptide complex of claim 101 or 102, wherein:VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to CDR1 SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 havingan amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054;VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059;VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

114. The antigen binding polypeptide complex of claim 101, 102, or 113, wherein:VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147;VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151;VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14;VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; andVH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

115. The antigen binding polypeptide complex of claim 101 or 102, wherein:VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 152 or 1045, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1046 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence atleast 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 153 or 766;VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054;VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059;VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 155 or 1047, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 156 or 1048, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 157, 767, or 1049.

116. The antigen binding polypeptide complex of claim 101, 102, or 115, wherein:VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147;VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 154;VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151;VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14;VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; andVH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 158.

117. The antigen binding polypeptide complex of claim 101 or 102, wherein:VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to CDR1 SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054;VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059;VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631.

118. The antigen binding polypeptide complex of claim 101, 102, or 117, wherein:VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147;VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151;VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14;VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; and VH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626.

119. The antigen binding polypeptide complex of claim 101 or 102, wherein:VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 152 or 1045, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1046 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 153 or 766;VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054;VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059;VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 155 or 1047, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 156 or 1048, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 157, 767, or 1049; and VH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631.

120. The antigen binding polypeptide complex of claim 101, 102, or 119, wherein:VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147;VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 154;VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151;VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14;VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 158; and VH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626.

121. The antigen binding polypeptide complex of claim 101 or 102, wherein:VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059;VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631;VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; andVH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054.

122. The antigen binding polypeptide complex of claim 101, 102, or 121, wherein:VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147;VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14;VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626;VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; andVH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151.

123. The antigen binding polypeptide complex of claim 101 or 102, wherein:VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059;VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631;VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; andVH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

124. The antigen binding polypeptide complex of claim 101, 102, or 123, wherein:VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147;VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14;VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626;VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; andVH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

125. The antigen binding polypeptide complex of claim 101 or 102, wherein:VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acidsequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631;VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059;VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20; andVH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054.

126. The antigen binding polypeptide complex of claim 101, 102, or 125, wherein:VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147;VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626;VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14;VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22; andVH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151.

127. The antigen binding polypeptide complex of claim 101 or 102, wherein:VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631;VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059;VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; andVH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

128. The antigen binding polypeptide complex of claim 101, 102, or 127, wherein:VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147;VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626;VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14;VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; andVH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

129. The antigen binding polypeptide complex of claim 101 or 102, wherein:VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 havingan amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059;VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20;VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; andVH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054.

130. The antigen binding polypeptide complex of claim 101, 102, or 129, wherein:VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147;VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14;VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22;VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; andVH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151.

131. The antigen binding polypeptide complex of claim 101 or 102, wherein:VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059;VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20;VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; andVH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631.

132. The antigen binding polypeptide complex of claim 101, 102, or 131, wherein:VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147;VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14;VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22;VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; andVH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626.

133. The antigen binding polypeptide complex of claim 101 or 102, wherein:VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence atleast 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20;VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059;VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; andVH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054.

134. The antigen binding polypeptide complex of claim 101, 102, or 133, wherein:VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147;VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22;VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14;VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; andVH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151.

135. The antigen binding polypeptide complex of claim 101 or 102, wherein:VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20;VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059;VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054; andVH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631.

136. The antigen binding polypeptide complex of claim 101, 102, or 135, wherein:VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147;VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22;VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14;VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151; andVH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626.

137. The antigen binding polypeptide complex of claim 101 or 102, wherein:VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 65 or 627, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 628 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence SDS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 66;VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;VH1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 12 or 1057, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 6 or 1058, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 13 or 1059;VH2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 148 or 1052, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 149 or 1053, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 150, 765, or 1054;VH3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 68 or 629, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 69 or 630, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 70 or 631; andVH4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 18, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 19, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 20.

138. The antigen binding polypeptide complex of claim 101, 102, or 137, wherein:VL1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 11;VL2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 147;VL3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 67;VL4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 17;VH1 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 14;VH2 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 151;VH3 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 71 or 626; andVH4 comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 21 or 22.

139. The antigen binding polypeptide complex of claim 101 or 102, wherein:VL1 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 9 or 1055, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1056 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence GAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 10;VL2 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 145 or 1050, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 1051 or an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence AAS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 146 or 764;VL3 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 15, a CDR2 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to amino acid sequence LGS, and a CDR3 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 16;VL4 comprises a CDR1 having an amino acid sequence at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical...

Images